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ABSTRACT
Emerging as an effective option, immunotherapy is gradually being recognized by
the cancer treatment community. However, due to its wide use of viral vectors for gene
delivery, many limitations and safety concerns impede its adoption in clinical practice.
This promotes the emergence of many non-viral gene delivery methods including the use
of inorganic or organic nanoparticles to carry and deliver genetic probes as complexes
through chemical mechanisms and the use of mechanical or electrical forces to physically
breakdown delivery barriers of the cell membrane to allow quick probe internalization.
Compared to the former (chemical methods), the latter (physical methods) shows
advantages in fast and efficient delivery performance, among which electroporation has
attracted the most attention in the past two decades. Electroporation designates the use of
short, high-voltage pulses to make the subjected cell membrane permeable. It has many
advantages like simple operation, quick delivery, non-restrictions on gene or cell types,
and low cost. However, compared to the viral delivery method, electroporation still faces
great challenges in terms of transfection efficiency. To solve these problems, we
developed a carbon nanotube (CNT) based micropillar array electrode (MAE) structure
and nanosecond electroporation pulse schemes to improve the overall transfection
performance of electroporation technology. The new carbon nanotube micropillar array
electrodes are used to replace the traditional aluminum plate electrodes. The superior
conductivity of CNTs on the micropillar surface makes the new electrode as good as their
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traditional counterparts in terms of conductance while its inert surface avoids undesired
electrochemical reactions and the release of Al3+ ions in the cell buffered solution which
are believed to be toxic to cells. More important, the epoxy base of the micropillars helps
partially embed those CNTs and fix them permanently on the electrode surface while the
exposed portion of CNTs serves as separated nanoelectrodes on the micropillar surface to
focus the electric pulse strength. This allows cells of different sizes to receive uniform
treatment during electroporation, resulting in significant improvement in the transfection
efficiency of genetic probes. Besides the CNT nanoelectrodes, we also applied
nanosecond pulses to further improve the transgene expression of electroporation by
deeper penetration than the traditional/standard millisecond electrical pulses. Under those
nanosecond electrical pulses, not only does the cell membrane becomes more fragile but
also the cell nuclear membrane becomes permeable. This allows genetic probes to enter
the cell nucleus more quickly to start the transcription process eventually speeding up the
overall transfection kinetics.
In this project, leukemia cells and carcinoma cells were used as the representative
suspension and adherent cell models respectively to demonstrate these two new
electroporation technologies. Plasmids encoding pMaxGFP and small interfering RNA
that precisely silence GFP translation were used as large and small genetic probe
representatives to test their delivery effectiveness. We found that carbon nanotube
micropillar array electrodes can achieve three times or more transfection efficiency than
the commercial electroporation counterparts without sacrificing cell viability. Combining
nanosecond and millisecond pulse scheme, the needed transgene expression time was
shortened by nearly 20 hours, demonstrating with GFP plasmids. These new
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electroporation technologies were further applied to treat model blood cells by mixing
primary blood cells with K562 cells at various ratios. The results show that our nano
electroporation system could double the transfection efficiency compared to the
commercial electroporation system for both plasmid and therapeutic microRNA, miR29b. The targeted protein level of miR-29b is further downregulated 20-25% from what is
achieved in commercial electroporation systems. Its success might further promote the
wide adoption of electroporation technology in cell immunotherapy.
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CHAPTER 1
INTRODUCTION

1.1
1.1.1

Research Hypothesis

Central Problems
Cancer is currently one of the most lethal and morbid diseases for human beings.

In recent years, immunotherapy has been used as a new and proven method in cancer
treatment. Immunotherapy strengthens the patient’s immune response to fight against
cancer and tumors by inducing stimulation and other methods (Kruger et al., 2019).
However, the viral transfection method widely used in immunotherapy carries significant
safety risks and long treatment duration. In addition, viral cancer immunotherapy requires
some in vitro transfection processes and multiple lymphatic injections during the
treatment period, causing great pain to patients.
Efficient non-viral transfection methods are more benign and are considered as
viral delivery alternatives as no safety concerns. Among different non-viral transfection
methods, electroporation is attractive in immunotherapy due to its many advantages such
as quick delivery and almost no restrictions on the cell type or delivery probes. However,
currently available electroporation technology still has several disadvantages, including
low transfection efficiency, high pulse voltage caused undesired effects, and
undiscriminating electroporation on cells regardless of their different sizes.
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2
1.1.2

Objectives
We propose some new electroporation technologies to improve their effectiveness

in immunotherapy. First, a Carbon Nanotube Micropillars Electroporation (CNTPs)
system is developed to improve the transfection efficiency for DNA and RNA probes
delivery. In this CNTPs system, cells are sandwiched between two plate electrodes with
one electrode made of carbon nanotube covered micropillars on the surface. When cells
are loaded onto its surface, the number of micropillars each cell faces varies with its size.
That means, for a large cell, it will receive more electroporation sites. As a consequence,
more hydrophilic pores will be produced on its cell membrane after electroporation than a
small cell. The carbon nanotubes on top of each micropillar make the pulse signal highly
concentrated in spots on the cell membrane at the nanometer resolution level.
Besides the advance of CNTPs on electroporation, we also look into the use of
pulse signals with nanosecond duration to further improve the electroporation
transfection efficiency and kinetics. Short nanosecond pulses were found useful to
increase the permeability of cell membranes and other membrane structures of
intracellular organelles, either temporarily or permanently (Beebe et al., 2003; Chopinet
et al., 2013; Ruzgys et al., 2018). Considering its potential to disrupting the nuclear
membrane (Tekle et al., 2005; Schoenbach et al., 2001), we hypothesize that appropriate
combination of nanosecond pulse treatment with traditional electroporation using
millisecond pulses might help promote quick nuclear entry of plasmids after their release
in the cytoplasm and transgene expression kinetics.

3
1.2

Approaches

Based on these hypotheses, carbon nanotube micropillars electrodes were
fabricated and applied in size-specific electroporation treatment. Briefly, SU-8
photoresist was first coated on a Si (100) wafer to create a micropillar array master mold.
A PDMS mold with a negative replica of the SU-8 micropillar structure was then coated
with a thin layer of carbon nanotube powder. The PDMS mold and another Si wafer piece
coated with another SU-8 photoresist layer were then pressed together and exposed under
UV light to solidify the SU-8 photoresist layer. After removing the PDMS mold,
micropillars of 2 µm in diameter and a pitch size of 2 µm (Figure 1-1a) were defined in a
12 mm ×12 mm region. On the surface of these SU-8 micropillars, carbon nanotubes are
partially embedded inside photoresist (Figure 1-1b). This not only ensures excellent
electrical conductivity for the whole micropillar electrode but also provides many
nanoelectrodes on the surface of those micropillars to further focus the electric pulse
strength and makes uniform pulse treatment on cell membrane regardless the different
sizes of those cells.
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Figure 1-1: (a) the SEM image of 2µm micropillar. (b) the SEM image of 2µm Carbon
Nanotube Micropillars.
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Furthermore, a home-made circuit board was used to generate nanosecond pulses

160mm
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(b)

II

and integrated into a flow-through nano-electroporation system. It includes three separate
Gold or carbon coated glass slide

units (a pulse generation unit, a power supply unit and a capacitor) which are connected
with an n-channel enhanced radio frequency metal-oxide-semiconductor field-effect
transistor (MOSFET). The nanosecond pulses with high pulse voltage were delivered in a
microfluidic channel which was milled on a piece of polymethyl methacrylate board.
Cells flow through the channel and pass the nanosecond pulsatile electric field to
complete treatment.
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(a)

(b)

Figure 1-2: (a) schematic of electric circuit design (b) schematic of the microfluidic
channel with Pt electrodes integrated on channel wall from both sides
We evaluated our hypotheses and concepts with these two new electroporation
technologies by looking into DNA and RNA probe delivery to both adherent cells (e.g.,
CT-26) and suspended cells (e.g., K562), as well as a model primary whole blood cells.
The delivery enhancement was evaluated by measuring the cell viability and transfection
efficiency of those targeting DNA and RNA probes.
1.3

Structure

Chapter 1 outlines the central problems and objectives of this research project. It
also introduces briefly our research approaches and organization of this dissertation.
Chapter 2 provides a literature review of relevant research work. This review includes
cancer immunotherapy options, gene transfection methods, electroporation mechanism
study, and current state-of-art micro/nano electroporation systems. Chapter 3
demonstrates the carbon nanotube micropillars electrode enhanced electroporation in
mammalian cell transfection. Chapter 4 demonstrates the nanosecond electroporation

6
scheme combining with millisecond pulses and its enhancement on mammalian cell
transfection. Chapter 5 demonstrates the coupling of these two new electroporation
technologies and the enhanced gene probe delivery in model whole blood samples.
Chapter 6 summarizes the results of the entire dissertation and recommends some work
worthy of further exploration.

CHAPTER 2
LITERATURE REVIEW

2.1

Cancer Therapy

Cancer is one of the world’s biggest public health problems. In 2018, there were
about 1,735,350 new cancer cases in the United States, and 609,640 cancer deaths were
projected (Siegel et al., 2018). As shown in Figure 2-1, cancer is one of the most fatal
diseases in the United States. For many years, people have been searching for cancer
treatments through surgery, chemotherapy, and radiation therapy (Figure 2-2). However,
these traditional treatments have some limitations, like poor effectiveness, and/or strong
side effects, which often seriously affect the life quality of patients. Some new
therapeutic drugs such as imatinib (Gleevec®) and trastuzumab (Herceptin®) have
emerged in the past two decades (Fischer et al., 2003). These drugs can target cancer
cells by homing in on specific molecular changes seen primarily in those cells. For
example, imatinib is a BCR-ABL kinase inhibitor that can inhibit the activity of tyrosine
kinase and promote the apoptosis of cancer cells (An et al., 2010). This kind of targeted
therapy has already become the standard treatment for many cancer treatments (Jabbour
& Hagop, 2018). However, because its significant side effects on harming to the patient’s
immune system, such as damaging the functions of human regulatory T cells and antigenpresenting cells (Mughal, 2010), scientists are continuously looking for new cancer
treatment methods that can inhibit the growth of cancer cells and tumors while still
7
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protect patient’s immune system.

Figure 2-1: Age-adjusted death rates for the ten leading causes of death in the United
States, 2016, and 2017.

2.2

Immunotherapy

With the development of molecular biology and immunology, immunotherapy has
emerged as a new attractive method in recent years and gradually become recognized by
the cancer treatment community (Khalil et al., 2016). There are two main types of
immunotherapy: active immunotherapy and passive immunotherapy. Active
immunotherapy can activate or stimulate the patient’s immune system, enabling its better
reorganization on tumor antigens or specific aggregation and consequence on tumor cell
attack (Davis, 2000; Oiseth & Aziz, 2017). Passive immunotherapy uses external
substances, such as monoclonal antibodies, lymphocytes, and cytokines, to exert
antitumor effects. In 2008, The New England Journal of Medicine reported a successful
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immunotherapy case for advanced melanoma treatment (Hunder et al., 2008). The patient
was a case of multiple metastases throughout the body. All the lesions of the patient
disappeared after being treated with autologous CD4+ T cells. The 2011 Nobel Prize in
Physiology or Medicine was also awarded to three scientists who were engaged in tumor
immunotherapy research (The Nobel Prize in Physiology or Medicine 2011). In 2018,
James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine
for their discovery of cancer therapy by inhibition of negative immune regulation (The
Nobel Prize in Physiology or Medicine 2018). These all bode well for the broad prospect
of immunotherapy in the field of malignant tumor treatment.

Figure 2-2: Cancer treatment options. Including Surgery, Hormone Therapy, Bone
Marrow Transplantation, Chemotherapy, Targeted Therapy, Radiation Therapy, and
Immunotherapy.
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2.2.1

Dendritic Cell-Based Immunotherapy
In immunotherapy, dendritic cell-based (DC) immunotherapy was the first one

that got approved by the U.S. Food and Drug Administration (FDA) in April 2010
(Cheever & Higano, 2011). DC immunotherapy uses the principle of antigen
presentation. DC cells can collect tumor antigens and present them to T cells to activate
them, and can promote targeted enrichment of T cells, which is a crucial antigenpresenting cell. DC cells are sparsely distributed in blood and tissues. In DC cell-based
immunotherapy, immature DCs were collected from whole blood or white blood cell
separation first. Then, artificial antigens were induced and expressed in DCs by mRNA
encoding tumor-associated antigens (TAAs) (Nair et al.,2002; Müller et al., 2004;
Nencioni et al., 2003; Milazzo et al., 2003) as peptides or proteins that carry tumor
antigens (Oneill & Nina, 2005). The mature DCs were then injected back into the
patient’s body via lymphatic injection, thereby stimulating T cells to complete the
immune response (Fujiwara et al., 2012; Roberts et al., 2016) (Figure 2-3). DC
immunotherapy was used to treat tumors caused by DC function lost or defected. Because
DC immunotherapy can help restore the specificity of activated T cells by repairing,
restoring, and enhancing the patient’s cellular immune function, it breaks the body’s
immune systemic and local tolerance state, thereby achieving systemic and local
reconstruction of the body’s immunity (Lesterhuis et al., 2011).
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Figure 2-3: Schematic of Dendritic cell-based (DC) immunotherapy principle.

2.2.2

Chimeric Antigen Receptor T-Cell Immunotherapy
Chimeric Antigen Receptor T-Cell Immunotherapy (CAR T-cell therapy) is

another representative immunotherapy method. In July 2017, the FDA approved
Novartis’s CAR T-cell product CTL019 in the treatment of relapsed or refractory
children and young B acute lymphoblastic leukemia (ALL) (Philippidis, 2017). In
addition to leukemia, CAR-T therapy is also widely used in some refractory lymphomas,
such as the treatment of B-cell non-Hodgkin lymphoma (NHL) (Chavez et al., 2019).
This therapy involves extracting T-cells from the patients’ Lymph node or Spinal cord,
followed by genetically modification in vitro using viral vectors to express artificial
Chimeric antigen receptor (CAR). CAR mainly includes three parts, namely the
extracellular single-chain variable fragment scFv, a transmembrane region, and a single
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intracellular activation signal CD3ζ or FcεRIγ (Srivastava & Stanley, 2015). Among
them, scFv is a single-chain antibody that can recognize tumor surface antigens outside
the cell membrane while CD3ζ or FcεRIγ is used for signal transmission. CAR can
stimulate T cells to carry out further immune responses after recognizing cancer cell
antigens, and the two are connected by transmembrane regions (Miliotou & Lefkothea,
2018) (Figure 2-4). After being modified and expressed in vitro, T-cells are further
expanded and eventually returned to the patient. Modified T cells can kill tumor cells
with more accurate identification and a much stronger effect than traditional
chemotherapy or radiotherapy. They will not disappear quickly even after the tumor cells
were eliminated and can circulate in the patient's body for a long time to monitor and
prevent the recurrence of cancer (Yáñez et al., 2019).

Figure 2-4: Schematic of CAR T-cell immunotherapy principle. (Miliotou and
Lefkothea, 2018)
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2.2.3

Natural Killer Cell Immunotherapy
Natural Killer cells (NK cell), with large particles in the cytoplasm, were

developed from bone marrow lymphoid stem cells, whose differentiation and
development depend on the bone marrow or thymus microenvironment. NK cells were
mainly distributed in peripheral blood and spleen. They can either directly contact and
kill target cells by rupturing their cell membrane or secrete perforin and tumor necrosis
factor to destroy target cells. Although NK cells are the leading members of innate antitumor immunity, tumors have also formed various strategies to escape NK cells from
trapping or impair NK cells’ function. These strategies greatly affect the actual
effectiveness of NK cell therapy (Sun et al., 2015; Veuillen et al., 2012; Reiners et al.,
2013; Paul et al., 2016). In 2018, A new antibody, named MAB-7C6 that targeted
MICA and MICB, was proposed to suppress the tumor's escape strategies (Andrade et al.,
2018). By isolating NK cells from human peripheral blood and using viral vectors to
induce the medication of NK cells and the secreting of this antibody, this new NK
therapy has achieved significant positive results in the treatment of lung cancer and
melanoma (Andrade et al., 2018). Similar to CAR-T therapy, Chimeric Antigen Receptor
Natural Killer (CAR-NK) cell immunotherapy is currently being extensively developed
(Ingegnere et al., 2019). In this combined immunotherapy strategy, CAR-NK cells are
genetically modified NK cells that can express specific antigens without being restricted
by autologous cells. Because it does not cause Graft-versus-host disease, this therapy is
very safe compared to other treatment options (Rubnitz et al., 2010; Miller et al., 2005;
Shaffer et al., 2016) (Figure 2-5).
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Figure 2-5: Natural Killer cells immunotherapy principle diagram. (Guillerey et al.,
2016)

2.3

The Shortcomings and Side Effects of Immunotherapy

Although immunotherapy achieves great success in cancer treatment, it yet has
several challenges in cytokine release syndrome (CRS) and off-target effects in
subsequent studies and clinical trials (Lee DW et al., 2015; Sun et al., 2018). Moreover,
the most severe problem for immunotherapy lies in its long time and much painful
treatment when extracting and implanting immune cells from the patient’s Lymph node
or spinal cord (Verdijk et al., 2009). The main reason for doing this comes from the fact
that the gene editing and genetic engineering tools all current therapeutic methods used
are based on viral vectors. This viral vector transduction requires collected cells to be
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treated in vitro for 24 to 48 hours before transfection, cells cultured in vitro, and another
72 to 96 hours following transfection with (Kochenderfer et al., 2010). Due to these
unavoidable requirements, the genetic modification process of immune cells can last
about 120 to 150 hours in vitro. Therefore, two Lymph node or spinal cord surgeries are
necessary for the whole therapy period which makes the patient suffer much pain.
Therefore, scientists are still looking for alternative ways to simplify the process of gene
transfection, which are expected to save time for genetic engineering, reduce patient
suffering, and ensure reasonable transfection efficiency and cell viability.
2.4
2.4.1

Gene Transfection Methods

Virus Vectors in Gene Delivery
Viral transduction is a eukaryotic gene transfer tool that is widely used in gene

therapy (Figure 2-6). Viral vectors used in viral transduction include retroviral vectors,
adenoviral vectors, lentiviral vectors, and herpes simplex virus vectors. Viral vectors can
infect target cells efficiently because they can encapsulate and protect their genetic
probes to effectively escape the lysosomal retention and deliver the carried gene probes
to the nucleus of target cells via microtubule transport. Compared with other methods,
gene delivery via viral vectors has unique advantages: (1) they have a broad host which
can infect both dividing and non-dividing cells and a high transfection efficiency for cells
that are difficult to transfect, such as primary cells, stem cells, and undifferentiated cells;
(2) viral vectors have a specific resistance to transcriptional silencing and can obtain
sustained and stable expression in the target cells; (3) viral vectors can be inserted into
tissue-specific promoters and enhancers to increase the transcriptional targeting
efficiency of specific gene probes, allowing targeted genetic probes to be expressed in
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specific cells or tissues. Because of these major advantages, viral vectors have become
widely adopted as a useful transfection tool to verify the function and effectiveness of
foreign genes in gene therapy.
Despite their many advantages, viral vectors, however, also have some
disadvantages that cannot be ignored. First, the packaging capacity limitation of a virus
cassette was considered to be smaller than 5 kbps. This makes the viral vectors very
difficult or impossible in some cases to encapsulate large or multifunctional plasmids
(Wu et al., 2010). Secondly, viral vectors have biosafety issues based on the clinical data
published in The New England Journal of Medical in 2002. After a successful practice on
the use of genetically manipulated hematopoietic stem cells to treat X-linked severe
combined immunodeficiency (SCID-X1) (Hacein-Bey-Abina et al., 2002), five of the
nine patients who received the treatment were diagnosed with leukemia after one year
(Hacein-Bey-Abina, 2003; Hacein-Bey-Abina et al., 2003; Mccormack & Terence H,
2004). Due to the integration of viral gene recombination, the human genes LMO2 (LIM
Domain Only 2) were abnormally activated. Although the toxic genes in our commonly
used viral vectors have been replaced by exogenous target genes, viral vectors still have
potential biological dangers as the primary source of lentiviral vectors is HIV while its
natural host is human. In current clinical trials, the use of gamma retroviral vector gene
transduction has a latency period of about three years, and the relative safety of HIVderived lentiviral vectors has not been followed up for a long time. So, more patients are
needed for this type of safety study and long-term risk of virus transduction for therapy is
still unclear (Pauwels et al., 2009).
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Figure 2-6: Virus gene vector types. (Worgall & Crystal, 2014)

2.4.2

Non-Viral Vectors in Gene Delivery
Because of the safety concerns and/or potential risks of the viral vector, non-viral

vectors drew great attention in gene delivery. Since 1987, many types of cationic
liposomes have been synthesized and tested for their performance in the non-viral
delivery of therapeutic probes (Felgner et al., 1987; Zhi et al., 2013). Cationic liposomes
are composed of two 12-18 hydrocarbon chains, two separated ends of which are
hydrophobic carbon molecules while the other end is a hydrophilic N+ cationic group.
Similar to what present in the cell membrane, cationic liposomes can form a double-layer
structure in water to bind and encapsulate genetic probes such as DNA and RNA as genelipid complexes, or lipoplexes (Zhi et al., 2010). These lipoplexes are formed by
electrostatic interactions between negatively charged genes and positively charged
cationic liposomes. The mechanism of cationic liposome-mediated gene transfection can
be briefly described as the positive charges on the surface of cationic liposome that
promote lipoplex absorption on the negatively charged cell membranes via electrostatic
interactions; the lipophilicity of liposome allows the gene-lipid complexes to enter cells
and form endosomes by intracellular endocytosis and cell membrane fusion; the genetic
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probes are then released into the cell cytosol and further into the nucleus to start
transcription (Zabner et al., 1995) (Figure 2-7). However, although the lipoplex delivery
method has several advantages such as a simple synthetic process, no immunogenicity,
and fast degradation in cells, this nonrival gene delivery method is much less effective
than its viral delivery counterparts and show more or less toxicity. For example, cationic
liposomes can activate caspase such as caspase-3 and caspase-9 which are the key
enzymes in the process of cell apoptosis and eventually cause cell death. Such cell
apoptosis potential increases as more cationic liposomes accumulate in cells and the
activity of caspase enzymes becomes more significant (Zuhorn et al., 2002).

Figure 2-7: Schematic of the Cationic Liposomes principle. (Behfar, 2013)

The calcium phosphate transfection method is another gene transfection method
that has been used since the early 1970s (Graham & A.J., 1973). Briefly, the target DNA
probes are mixed with calcium chloride in phosphate buffer to form a calciumphosphate–DNA co-precipitates. The co-precipitates are then co-cultured with cells and
the calcium-phosphate-DNA co-precipitates enter cell cytoplasm by endocytosis. The
major components required for this transfection method are readily available and
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inexpensive. However, the transfection efficiency of this method is susceptible to pH
value, temperature, and buffer ion concentration in the transfection environment
(Chalberg et al., 2005). Moreover, like lipoplex, it shows toxicity to various cells. So
many types of primary cells, its application range is quite limited compared to other
transfection methods (Zauner et al., 1996).
Other than the chemical non-viral delivery method, physical approaches such as
gene gun and electroporation (which is introduced in the next section separately) were
also explored for potential gene delivery. Gene gun or particle bombardment method is a
mature gene delivery method. In 1987, the earliest gene gun technology was developed
by John C. Sanford (Sanford et al., 1987). Gold or tungsten particles were used in this
method as a gene vector, which was sent to cells by the power of compressed nitrogen, or
helium gas (Oard et al., 1990; Sautter et al., 1991) (Figure 2-8). In gene gun, target
genetic material is attached to those inorganic nanoparticles and is directly ingested into
animal or plant cells, or organelles that need to be engineered to achieve gene transfer. As
a purely physical method, it can perform gene transfer for any target cell with no strict
requirement on the size of genetic probes and no long-term unpredictable safety concerns
(Wang & Yu, 2003). However, compared to the other gene delivery methods, the number
of cells that can be treated by this method is very limited and the gene gun equipment and
bullets are expensive (Davies, 2004).
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Figure 2-8: Schematic of the working principle of the Gene Gun. (Muhammad, 2019)

2.5
2.5.1

Electroporation in Molecules Delivery

Introduction
In the past few decades, electroporation has been widely employed as the major

physical method to facilitate intracellular delivery of nucleic acids (such as DNA
plasmids, mRNA, siRNA, and microRNA) besides its applications in other different areas
like drug delivery (Figure 2-10). Electroporation has outstanding performance in many
aspects, such as reasonable transfection efficiency, short transfection time, safety, easy
operation, and non-restrictions on the type of cells and genetic probes.
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Electroporation research started from the late 1950s and showed that the cell
membrane would reversibly breakdown when a pulsatile electric field was applied to
cells with appropriate pulse duration (Stämpfli & M. Willi, 1957). In 1972, the name
“electroporation” appeared in a report that showed the permeability of the cell membrane
would be increased upon applying an electric field (Turnbull et al., 1973). Neumann and
Zimmermann first designed it as an electrically mediated gene delivery system in 1982
(Neumann et al., 1982). Since then, electroporation has been redesigned and optimized
many times prior to serving as a mature gene delivery tool today.
During electroporation, cells are placed in an external electric field for a short
period. Under the influence of the transmembrane potential, the conductivity and
permeability of the plasma membrane of the subjected cells are increased, and the
charged foreign materials are allowed to enter the cell cytoplasm (Rols et al., 1998). Due
to the massive resistance of the phospholipid bilayer of the cell membrane, the voltage
from the electric pulse is imposed mainly on the cell membrane, other than the nuclear
membrane or membrane for organelles inside cells. Therefore, the electric field allows
DNA and other substances to cross the cell membrane and stop nearby in electroporation.
Subsequent transport of these substances inside the cell, for example, their entry to the
nucleus, still relies on other mechanisms (Weaver, 2003).
Several hypothetical mechanisms were proposed to explain how a pulsatile
external electric field would temporarily improve the permeability of cell membranes
during electroporation. It is generally believed that the transmembrane voltage acting on
the stratum corneum can form transient aqueous passageways across the cell membrane
under short electrical pulses, which causes structural rearrangements of the membrane
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phospholipids. Hydrophilic pores are formed in the lipid bilayer of the cell membrane,
which allows drugs or gene probes to travel across the cell membrane directly in a short
time (Weaver, 1995) (Figure. 2-9). After the treatment, the hydrophilic pores on the cell
membrane will disappear and the cell membrane will be resealed. However, if the electric
field energy becomes too high and the exposure time becomes too long, the cell
membrane will be irreversibly damaged, which will eventually lead to cell death (Han et
al., 2003; Wang & Chang Lu, 2006; Bao et al., 2008).

Figure 2-9: (a) Normal cell membrane, (b) A cell excited by short electrical pulse
resulting in irregular molecular structure, (c) The membrane being notched, (d) The cell
with a temporary hydrophobic pore, and (e) The cell with a hydrophilic pore after
membrane restructuring (Wu et al., 2004)
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Figure 2-10: Electroporation of a cell may be reversible or irreversible. Irreversible
electroporation can lead to cell apoptosis and be used to treat cancer. Reversible
electroporation can be optimized for the introduction of small and large molecules, the
fusion of cells, and the insertion of proteins into the cell membrane (Matej & Damijan,
2010).
The transmembrane potential initiated by the external electric field is usually
estimated by：
3

𝑡

𝛥𝑉 = 2 𝑟𝐸𝑒𝑥𝑡 cos 𝜃 [1 − 𝑒𝑥𝑝 (− 𝜏 )]
𝑚

Eq. 2-1

where 𝛥𝑉 is the transmembrane potential, 𝑟 is the radius of the cell, 𝐸𝑒𝑥𝑡 is the
electric field strength, 𝜃 is the angle between the electric field direction and the
membrane surface, 𝑡 is the time after the electric pulse onset, 𝜏𝑚 is the membrane
charging time constant, given by:
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𝜏𝑚 =

𝑟𝜀𝑚
𝜎𝑖 𝜎𝑒
2𝑑𝜎 +2𝜎 +𝑟𝜎𝑚
𝑒
𝑖

Eq. 2-2

where 𝜎𝑖 is the conductivity of the cytoplasm, 𝜎𝑚 is the conductivity of the cell
membrane, 𝜎𝑒 is the conductivity of the extracellular medium, 𝜀𝑚 is the dielectric
permittivity of the membrane, and 𝑑 is the cell membrane’s thickness (Schwan, 1957;
Kotnik et al., 2012; Gimsa & Derk, 2001).
2.5.2

Electrical Factors in Electroporation
According to the above equation (Eq. 2-1; Eq. 2-2), we can identify several

factors that influence the electroporation process:
Cell membrane conductivity and medium conductivity are two vital factors.
According to Eq. 2-2, we can find out that the cell membrane conductivity and medium
conductivity determine not only the transmembrane potential but also the charging rate of
the transmembrane potential. If the cell membrane and medium conductivity are high, the
system resistance is small. Under a specific voltage condition, the current will increase,
and more heat will be generated, which will lead to a decrease of cell viability. For
bacterial cells, electroporation systems require low-conductivity, high-resistance media to
prevent arcing at high voltages during the process, because bacterial transfection always
requires high voltages. However, for mammalian cells, the voltage required in the system
is relatively low, so a medium with relatively high conductivity and low resistance is
needed to increase the transfection efficiency of electroporation.
Pulse waveform type also affects the efficiency of electroporation. There are two
main types of pulse waveforms: square wave pulse and exponentially decaying wave
pulse. A square wave pulse refers to the voltage instantly rises to a preset voltage and is
maintained at that level for a period and then the discharge is terminated immediately.
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Generally, square wave pulses are selected for the transfection of mammalian cells. The
exponentially decaying wave pulse refers to the charge of a capacitor first, followed by
the discharge of the capacitor completely so that the voltage decays exponentially. This
type of pulse is suitable for bacteria, yeast, and insect cells.
Pulse time (duration) is another important factor. The selection of the pulse time
mainly depends on the pulse waveform. In the square wave pulse, the pulse time can be
set directly. In the exponentially decreasing wave pulse, the pulse time refers to the time
it takes for the voltage to decay to one-third of the initial voltage (i.e., the maximum
voltage), which is equal to the product of the capacitance (C) and resistance (R). In the
parameter optimization process, increasing the pulse voltage should be accompanied by
the reduction of the pulse duration to balance the transfection efficiency and the viability
of the cells.
2.5.3

Non-Electrical Factors in Electroporation
Besides the several electrical signal related factors mentioned above, the

electroporation result is also determined by some other factors.
(1)

Cell size. According to the first equation (Eq. 2-1), we can see that the cell

radius (or cell size) is also a critical factor. A giant cell gains a high transmembrane
potential, and similarly, a small cell receives a low transmembrane potential. This
coefficient is more difficult to control during the actual electroporation process because
the cell size varies wildly. Even in the same cell type, the cell size is the same under
different division stages or nutritional conditions. Current commercial electroporation
instruments can only set one parameter of the electric field to satisfy the appropriate
transmembrane potential for a certain type of size in their average size during an
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electroporation process. Therefore, the electroporation results are often not very
consistent when the cell is significantly different from batch to batch.
(2)

Cell state. The cells used for an electroporation test are generally selected

in the logarithmic growth phase (within 15 generations, two days after subculturing). Due
to the vigorous cell division in the logarithmic growth phase, the surface structure is
looser than stable phase cells. After electroporation, the cell membrane has a strong
recovery ability, and the followed the mitotic phase of cells is more likely to accept the
foreign gene probe.
(3)

Genetic probe. The size of the gene probe affects its cell uptake efficiency

during electroporation. Generally, small fragments of probes are naturally easier to get
introduced in cells than large fragments. Also, the transfection efficiency increases for
samples with higher probe concentration within a specific range. However, after reaching
the maximal value, further increase of the probe concentration actually would drag down
the transfection efficiency and cell viability gradually. This phenomenon might be caused
by the existence of saturation of genetic probes in cells. Further high concentration would
change significantly the osmotic pressure or other conditions inside cells that affect the
functions and viability of cells. As a result, the overall transfection efficiency decreases.
2.5.4

Nanosecond Pulses Electroporation
The electrical pulses used in the ordinary commercial electroporation system are

millisecond electrical pulses. Millisecond electrical pulses can cause an imbalance in the
electric charge on both sides of the cell membrane and induce the bilayer of
phospholipids to move, thereby forming hydrophilic pores (Weaver 2000). Later, it was
discovered that during the electroporation process, when the duration of the electrical
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pulse was reduced from milliseconds to nanoseconds, and the electric field strength
increased to 100KV/cm, it will cause a range of different cellular responses inside the
cell, such as the nucleus, mitochondria, and endoplasmic reticula(Schoenbach et al.,
2001; Schoenbach et al., 2004), though there is no obvious electroporation hydrophilic
pore on the cell membrane surface. Many micronuclei will be produced in cells and cells
will be induced to enter programmed death. This phenomenon is defined as Intracellular
Electromanipulation (IEM) (Beebe et al., 2002). Some explanations suggest that IEM
occurs because nanosecond electrical pulses can generate large transmembrane potentials
on the membrane of organelles. When the transmembrane potential of organelle
membranes exceeds a critical value, electroporation will occur on these organelles’
membrane. The nanosecond electrical pulse produces a small transmembrane potential on
the outside cell membrane so the cell membrane may become fragile, but no obvious
electroporation occurs (He et al., 2017; Breton & Lluis, 2012; Qi et al., 2014).
In 2008, Vermier found that nanosecond pulses can promote the release of
calcium ions in cells. He used a calcium-sensitive fluorescent material, calcium green to
label chromaffin cells, and then treated them with nanosecond pulses. He found that the
fluorescence intensity of the treated cells was enhanced. This proves that nanosecond
pulses can increase the flow of calcium ions. In 2004, Chen used the fluorescent dye
Acridine Orange (AO) to label HL-60 cells and then treated them with nanosecond
electric pulses. They observed through confocal microscopy that the fluorescence
intensity of the nucleus of cells was reduced after treated with nanosecond electric pulses.
This shows that the number of AO-DNA complexes in the nucleus is reduced. Chen
explained that the nanosecond pulses caused an increase in the permeability of the
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nuclear membrane, which caused the AO-DNA complex to flow out of the nucleus (Chen
et al., 2004).
A few attempts later looked into the potential of nanosecond pulses for gene
delivery, in principle, could improve the permeability of cell nuclear membrane (Beebe et
al., 2006; Chopinet et al., 2013; Ruzgys et al., 2018). However, owing to its ultra-short
pulse duration and ineffectiveness on breaking down the cell plasma membrane,
disappointing gene transfection results are mostly found unless extremely high field
strength was applied in some cases (Ford et al., 2010). But this is often tied with low cell
viability because of the severe side effects associated with the applied high electrical
voltage (Pakhomoya et al., 2011; Kim et al., 2007; Movahed & Li, 2010; Wang et al.,
2009; Chang et al., 2016). DNA transfection with nanosecond pulse treatment still faces
substantial challenges to receive both desirable gene expression and cell viability.
2.5.5

Micro-/Nanofluidics Based Cell Electroporation
The high-voltage pulses in electroporation, though effective in improving the cell

membrane permeability and probe uptake, inevitably leads to severe side effects
detrimental to later cell survival (Movahed & Li, 2010; Kim et al., 2007; Wang et al., 2009)
such as Joule heating and pH change to nearby treated cells. The available protocols of the
electroporation are therefore established by trial-and-error by balancing acceptable
transfection efficiency and cell viability. Many new electroporation setups with micro/nanoscale features have been developed to overcome these challenges. In these new
systems, either electrode pairs are closely patterned (Lee & Tai, 1999; Lin et al., 2001; Lu
& Jensen, 2005; Guignet & Tobias, 2008; Dalmay et al., 2011; Garcia et al., 2016) or
micro/nanofluidic channel constriction are integrated (Kurosawa et al., 2006; Wang & Lu,
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2006; Khine et al., 2005; Huang & Boris, 2001; Shin et al., 2004; Fox et al., 2006; Lee et
al., 2009; Kim et al., 2011).
In this way, a very low voltage across the electrode pair can generate pulses with
high enough field strength, such as 500-1000V/cm, to accomplish cell membrane
breakdown. The introduction of microfluidic components in these systems can also
mitigate the adverse effects of traditional commercial electroporation systems such as
water electrolysis, bubble formation, poor electrochemical activity, and Joule heating, all
associated with the high-voltage pulses employed in traditional electroporation. In
addition, the low voltage may also minimize the extra damage to the treated cells and
prevent them from losing too many intracellular components (Huang & Boris, 1999;
Valero et al., 2008; Shin et al., 2004). Besides the major advantages of reducing the pulse
voltage, microfluidics-based electroporation offers new advantages over the commercial
systems, namely in situ monitoring of intracellular content transport and electroporation
dynamics at the single-cell level. Furthermore, it could also provide flexible treatment
throughput on cell numbers to satisfy various demands from different applications on
electroporation. For example, the transfection of a single cell or a few cells is suitable and
sufficient for cell biology analysis and transgenesis. But for therapeutic practice, largerscale transfection with a cell number in the order of 105-109 is required. As for cell-based
bioreactors to produce therapeutic protein, the preferred cell numbers are generally in the
billions or higher. Several research groups have demonstrated that flexible scale cell
transfection in low-voltage, microfluidic electroporation by designing microchannel
arrays (Munce et al., 2004; Khine et al., 2005; Khine et al., 2007; Ionescu-Zanetti et al.,
2008; Kim et al., 2008). The use of fluid systems not only allows continuous processing
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of many cells for high-throughput electroporation but also helps to change the
permeability of the cell membrane and improve the performance of electroporation
(Wang et al., 2010).
Although these micro-/nanofluidic-based cell electroporation systems show
great potentials to advance future life science and medical research, their delivery
performance and reliability have not yet been comprehensively examined. Most of them
stay on the quick concept demonstration stage to deliver fluorescence dyes, small
chemicals, and at most, DNA plasmids or RNA probes in model cell lines of mammalian
cells, yeast, and bacteria. Data on valuable therapeutic probes and clinically important
primary cells or patient samples still largely lacks. In addition, most of these micro/nanoscale systems have relatively complicated operation procedures, not easy for endusers other than trained engineers such as biologists and medical doctors to operate and
adapt to their current setup and procedures. More efforts should be given to clear these
barriers before their applications in clinic practice, besides the general expectation for
any new therapeutic methods on higher delivery efficiency with precise treatment, quickexpression, and the consequent appropriate cell viability for those cells and probes. This
provides additional challenges and opportunities for the next generation micro-/nanoscale
electroporation technologies.

CHAPTER 3
CARBON NANOTUBE MICROPILLARS ARRAY ELECTRODE
ENHANCED ELECTROPORATION IN MAMMALIAN CELL
TRANSFECTION

3.1

Introduction

Electroporation is widely used for DNA and RNA probe transfection. Hydrophilic
pores are formed on the lipid bilayer of a cell membrane when an appropriate electric
pulse is imposed on, which allow drugs or gene probes to travel across in a short period
before the resealing of the cell membrane (Weaver, 1995). It has advantages like quick
delivery process, acceptable cell viability and gene transfection rate, and no limitation to
cell types or transfection agents. The electrodes used in conventional electroporation
systems from Harvard Apparatus, Bio-Rad, Eppendorf, Mirus Bio are aluminum parallel
electrodes on two sides of a cuvette. Electric pulses with a field strength of several
hundreds to thousands and application duration of milliseconds are applied between these
two electrodes to accomplish breakdown of the cell membrane. However, this type of
electroporation configuration ignores the local electrical variations on individual cells of
a large population, leaving many factors uncontrolled. Based on Equation 2-1, besides
the electric field strength, the needed transmembrane potential is also related to the size
of the treated cell and the conductivity of the electroporation medium. Nevertheless, the
simple parallel-plate plain electrode setup is currently available electroporation systems
cannot fix these problems.
31

32
In this chapter, we introduce a new electrode configuration and integrate it into a
new electroporation system, namely Carbon Nanotube Micropillars Electroporation
(CNTPs) system. In this system, carbon nanotube coated polymer micropillar array is
fabricated to implement size-specific electroporation. These carbon nanotubes (CNTs)
offer the needed electrical conductivity of the micropillar array structure while the
polymer base holds CNTs to avoid falling off the electrode surface during the pulse-on
time to cause additional toxicity to the treated cells. CNTs also offer comparable
conductivity as a metal electrode while eliminating the potential introduction of
unwanted metal ions in the electroporation medium, which are found toxic to cells. The
nanoscale structure on these CNT nanoelectrodes can highly focus the electric field in
many nanoscale locations, thereby achieving uniform electroporation on cells of different
sizes. We evaluated the transfection enhancement of this CNT pillar array nanoelectrode
with reporter DNA plasmids (pMaxGFP), siRNA, and microRNA probes. Human
leukemia cells (i.e., K562 cells) were tested to demonstrate its effectiveness.
3.2
3.2.1

Materials and Methods

Materials and Reagents
DNA plasmids probe with pMaxGFP reporter genes were purchased from Lonza,

Inc. siRNA used for silencing pMaxGFP were synthesized by Thermo Scientific
(Pittsburgh, PA) and the sequences were as follows: siRNA for GFP silence, sense strand,
5-CGCAUGACCAACAAGAUGAUU-3; antisense strand, 5UCAUCUUGUUGGUCAUGCGGC-3. All other cell culture reagents were purchased
from Life Technologies (Carlsbad, CA), and all the chemicals were purchased from
Sigma-Aldrich unless specified.
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3.2.2

Cell Culture
K562 cells (ATCC, CCL-243) and CT26.WT cells (ATCC, CRL-2638) were used

in the electroporation test. These cells were cultured in RPMI 1640 medium
(supplemented with 10% FBS, 1% L-Glutamine, and Penicillin/streptomycin). All
cultures were maintained at 37 ℃with 5% CO2 and 100% relative humidity.
3.2.3

Carbon Nanotube Micropillar Array Electrode Fabrication
A piece of SU-8 Micropillars Array on Si wafer was cleaned by acetone, IPA and

DI water and dried in an oven at 50 ℃, as the master mold. After that, a mixture of
PDMS precursor with the curing agent at a 10:1 ratio was cast on the surface of the mold.
After 4 hours of curing at 60 ℃, the cross-linked PDMS layer was carefully cut and
peeled off the SU-8 master mold. Carbon nanotubes (CNTs) were then applied to the
PDMS mold surface and rubbed to get a thin layer of CNTs coated on the PDMS mold.
Another blank Si chip was cleaned by acetone, IPA, and DI water and dried by a
nitrogen gun. After that, a thin layer of SU-8 2002 photoresist was then coated on this
cleaned Si chip. The CNTs coated PDMS mold was then pressed into the SU-8 layer on
the Si chip. The whole pieces (PDMS, CNTs, SU-8 layer, and Si chip) were then
sandwiched between two pieces of glass slides using document clips. Because uncured
SU-8 photoresist is stickier than the PDMS mold surface, the pressing force pushes CNTs
into the SU-8 coating layer, so makes the microwell pattern on PDMS mold (the negative
replica of micropillar array from the Si master mold). After exposed under a UV light for
5 min, SU-8 2002 layer are cross-linked and was further solidified with hard baking at
100 ℃ for 1 hour. Finally, the PDMS mold was carefully removed from the silicon chip,
leaving SU-8 micropillars with CNTs coated on their surface top. In CNT bundles, the
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bottom part was embedded in SU-8 and the top part exposed, forming small bumps at the
nanometer scale on the surface of micropillars as nanoelectrodes. When cells are placed
on them, these protruded CNTs will contact and delivery electric pulses on the cell
membrane.
3.2.4

CNTPs Electroporation Setup and Operation Procedure
Cells were first centrifuged and re-suspended in fresh OPTI-MEM I (a serum-free

medium) at a density of 2.5×107 cells/ml. Plasmid DNA (pMaxGFP) of 1 µg was then
added in each electroporation sample (total volume of each sample is 5 µL). These
samples were loaded onto the CNTPs surface (CNTPs was considered as a positive
electrode). A piece of ITO-coated Glass (ITO Coated Glass was considered as a negative
electrode) with a PDMS gasket (~200 µm thickness) was then placed from the top of a
cell sample to hold the electroporation solution. Electric pulses were added on these
samples with the following pulse conditions: 2.5 kV/cm of the pulse strength and single
10-ms pulse with a rectangular pulse profile. After electroporation, the ITO-coated Glass
was removed, and cells were washed off from the CNTP electrode. They were collected
and transferred to 12-well plates and cultured for 24 hours at 37 ℃ with 5% CO2 and
100% relative humidity before further analysis.
3.2.5

Transfection Efficiency and Cell Viability
The expression of pMaxGFP plasmids is evaluated both qualitatively by

visualizing cells with green fluorescence within some representative areas under an
inverted fluorescence microscope (Olympus, Japan) and quantitatively by counting cells
using a flow-cytometer (CytoFLEX PN B49006AE) with a laser wavelength of 495 to
519 nm. The results were analyzed with Cytexpert software, and 10,000 events were
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counted for each sample. The transfection efficiency of pMaxGFP is defined as the
number of cells emitting fluorescence signal to the total number of cells in a sample
(gated fluorescence signal of GFP).
The cell viability was evaluated by an MTS cell proliferation assay (Promega,
Madison, WI). Briefly, 100 μL cells 24 hr post-electroporation from each sample were
transferred to a 96-well plate, and CellTiter 96 AQueous One solution (Promega,
Madison, WI) of 20 μL was added to each well, and all samples were incubated at 37 ℃
for 1 hr. Absorbance was measured at 492 nm on an automated plate reader (Elx 800,
Biotek, VT). Data points were represented as the mean ±standard deviation (SD) of
triplicates unless otherwise indicated. The cell viability is calculated as the absorbance
signal ratio of an electroporated cell sample to that of the negative control cell sample in
MTS assay, after extracting the absorbance background from the media.
3.2.6

Determination of MicroRNA Delivery Efficiency
The miR-29b delivery efficiency was evaluated from two aspects: first, the

expression level of miR-29b. Second, the downregulation performance or expression
level of target genes, including CDK6, DNMT38B, and MCL1. To measure the
expression levels, the total RNA was first reverse transcribed into cDNA, and a RealtimePCR was conducted. The expression level was determined by the ΔΔCt method and
normalized to endogenous controls.
3.2.7

Total RNA Extraction
Total RNA was extracted using TRIzol reagent (Life Technologies, Carlsbad,

CA). Cells were harvested by centrifugation and the culture medium was removed. After
that, 250 µl TRIzol reagent was added to each sample (containing approximately 8 to
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10x105 cells). Samples were lysed by pipetting several times and incubated for 5 min at
room temperature. The nucleoprotein complex was dissociated completely. Chloroform
of 125 µl was added to each sample and the tubes were shaken vigorously for 15 s
followed by 3 min incubation at room temperature. Then, all samples were centrifuged
with 12,000 rpm for 15 min at 4 ℃ to separate into a colorless upper aqueous phase,
interphase, and a lower red chloroform phase. The upper aqueous phase was transferred
into new tubes by gentle pipetting without drawing any of the interphases, and 500 µl
100% isopropanol was added into each of aqueous phase tubes, followed by 10 min
incubation at room temperature. The samples were centrifuged at 12,000 rpm for 10 min
at 4 ℃ and the supernatant was discarded. To wash the RNA pellet, 200 µl 75% ethanol
was added into each tube and samples were vortexed briefly and centrifuged at 7500 rpm
for 5 min at 4 ℃. After removing the supernatant, the RNA pellets were air-dried for 5 to
10 min. 20 µl RNase-free water was then added into each tube and all samples were
incubated at 60 ℃ for 10 min. Then the RNA samples were ready for reverse
transcription.
3.2.8

Reverse Transcription PCR
The Taqman® microRNA Reverse Transcription Kit (Life Technologies,

Carlsbad, CA) was used for microRNAs reverse transcription. The reagents were first
allowed to thaw on ice. The total volume of 15 µl reaction was prepared in a
polypropylene tube, including 0.15 µl dNTP mix (100 mM total), 1 µl MultiscribeTM RT
enzyme (50 U/µl), 1.5 µl 10X RT PCR buffer, 0.19 µl RNase inhibitor (20 U/µl), 4.16 µl
nuclease-free water, 3 µl primer and 5 µl RNA sample (1000 ng). The thermal cycler was
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programmed as follows: 30 min at 16 ℃, 30 min at 42 ℃, 5 min at 85 ℃ and hold at
4 ℃.
3.2.9

qRT-PCR Amplification
The resulting cDNA from reverse transcription reaction was amplified by qRT-

PCR with TaqMan™ Gene Expression Master Mix (Thermo Scientific, Pittsburgh, PA).
The total volume of 20 µl reaction was prepared in a polypropylene tube, including 10 µl
TaqMan™ Gene Expression Master Mix, 1 µl 20 X TaqMan® assay and 9 µl cDNA
template. The thermal cycler was programmed as follows: 10 min at 95 ℃ for
polymerase activation, then 40 PCR cycles with 15 seconds at 95 ℃ for denaturing and 1
min at 60 ℃ for annealing. The relative gene expression was determined by the ΔΔCt
method. The mature miR-29b expression was normalized to endogenous control RNU48
and relative to the untreated control cells. The expression of CDK6, DNMT3B, and
MCL1 mRNAs was normalized to endogenous controlled GAPDH and relative to the
untreated controlled cells.
3.3
3.3.1

Results and Discussion

CNTs Modified Micropillars
The motivation of creating micropillars on the electrode surface is to treat

different sizes of cells at the same time in the same condition. In other words, the cells
cover more of micropillars that received the focused electric field on more spots of their
cell membrane. We designed and fabricated CNT coated micropillar arrays with each
micropillar having a diameter of 2 µm and height about 2 µm, as shown in Figure 3-1(a)
of the low magnification SEM images of micropillars. Figure 3-1(b) focuses on a single
micropillar, Figure 3-1(c) shows its top with many CNTs protruded on the surface, and
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Figure 3-1(d) gives schematically an overall view on CNTs coated micropillar array
electrode. The rough surface around micropillars was caused by CNTs embedded in the
SU-8 layer.

(a)

(b)

(c)

(d)

Figure 3-1: SEM images of CNTs coated micropillar electrode (a) 8K magnification
of micropillar array; (b) single pillar at 30K magnification; (c) the top surface of a
micropillar at 100K magnification; (d) schematic of an overall CNTs coated
micropillar electrode.
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3.3.2

CNT & CNTPs Enhancement on Gene Transfection
In this CNTP electrode, CNTs are employed to provide more electroporation spots

on the cell membrane with nanoscale resolution. Because of their excellent conductivity,
CNTs coated on the SU-8 layer, which included the exposed part and embedded part,
make the micropillar conductive enough to serve as an electrode. The exposed part of the
CNTs on the surface of micropillars further creates much higher focused electric field
strength on the cell membrane area they face. As those exposed CNT parts disperse
randomly on the micropillar top, each in the nanometer scale, more electroporation spots
are generated on the cell membrane when cells approach the CNTP electrode during
electroporation. With a surface resistance of around 2 MΩ, the CNT coated micropillar
electrode needs a voltage of around 50 V (8.3 kV/cm) to achieve a high transfection rate
in k562 after optimization. As a comparison, the parallel-plate plain aluminum electrodes
in commercial cuvette type systems require 220 V (550 V/cm). Figure. 3-2(a), shows the
phase contrast and fluorescent images of GFP expression of K562 cells 24 hours after
transfection with traditional electroporation (designated as msEP) and electroporation
systems with CNT coated plain plate electrodes (designated as CNT), and CNT coated
micropillar electrode (designated as CNTP). The CNT coated plain plate electrodes
achieves an enhanced transfection of the GFP plasmids about 12% from msEP (31.5% ±
0.6%), reaching 43.21% ±3% and a cell viability of 81.43% ±2% when compared to
88.72% ±0.7% from msEP. After introducing the micropillar structure on the electrode
besides CNT coating (CNTP), the transgene expression of GFP plasmid significantly
ameliorates to 84.75% ± 1% with the viability of 80.21 ±1%. Such transfection
performance differences of CNTPs, CNT, and msEP are caused by the focused pulse on
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nanoscale spots on the top of the micropillar electrode and the automatic allocation of
those electroporation spots on cell membrane regardless of the different sizes of cells and
their random dispersion status on the electrode. In Figure 3-2(b), the left side is the GFP
plasmid transfection percentage, and the right side is fluorescence intensity. The latter
represents the average fluorescence intensity in treated cells, which reflects the average
quantity of GFP plasmids loaded in each cell while the former indicates the percentage of
cells that have successful GFP plasmid delivery, estimating the number of cells gets
transfected successfully. Comparing to the msEP, the CNT and CNTPs electrodes
achieve 6 folds and 22 folds of the transgene expression of GFP plasmids in K562 cells
when compared with what is achieved in msEP case. The CNTP case enhances a 2.6 fold
increase in the transfection percentage (i.e., successfully transfected cell number of
treated cells).
Such improvement on the transfection quality and quantity with CNTP electrode
as the result of more nanoscale focused spots on cell membranes contributed from the
protruded CNTs on the SU-8 pillar surface. Their small cross-section provide a more
focused pulse while their large quantity splits the electroporation area on the cell
membrane to many isolated, tiny spots. In this way, the cell membrane could get a large
area affected by the electric pulses, having hydrophilic pores in many locations, each
averagely smaller than what occurs in conventional electroporation with plain plate
electrode. This not only offers significantly increased port number on the cell membrane
to allow genetic probe transport across the cell membrane but also makes it easier to
reseal later due to the small pore size in each spot. With a well-patterned micropillar
array on the electrode, cells of different sizes sitting on the micropillar top receive around
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the same current density of electric pulses during electroporation. That is, a large cell
covers more micropillars than a small one and the number of electroporation spots each
cell receives is determined by the surface area on its cell membrane facing the CNTP
electrode. In this way, a similar electroporation level is accomplished for cells of
different sizes in one sample. In Figure 3-3, the flow cytometry dot plot of msEP has
shown that there is lower transfection on smaller cells while there is higher transfection
on medium-sized cells. But for electroporation systems with CNT and CNTP electrodes,
more cells of various sizes get GFP plasmids delivered. GFP positive cells population
spread towards both large and small cell subgroups significantly.
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（a）

（b）

（c）

Figure 3-2: The transfection and cell viability of K562 cells in three different cell
transfection methods with a cell concentration of 107 cells/mL. (a) The phase contrast
and fluorescent images, (b) quantitative transgene expression, fluorescence intensity,
and (c) cell viability of samples 24 hrs after transfection. The images are in order of
msEP, CNT, and CNTPs. The transgene expression is presented as both transfection
efficiency for the number percentage of GFP positive cells (left group data in panel b)
and mean fluorescence intensity for average GFP dosage in individual cells (divided by
a factor of 105, right group data in panel b). The same color codes are applied in panels
b and c. Significance t-test was performed with n=3 with **P < 0.01) and compared to
msEP alone treatment.
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(a)

(b)

(c)

Figure 3-3: The flow cytometry dot plots of (a) msEP, (b) CNT, and (d) CNTPs.

3.3.3

CNTPs Enhanced siRNA Delivery
To further demonstrate the effectiveness of CNTPs to RNA probe delivery, we

chose small interfering RNA (siRNA) with sequences that could specifically silence the
expression of GFP. Their knockdown efficiency was evaluated by co-transfecting with
pMaxGFP plasmids. As shown in Figure 3-4, apparent suppression of GFP expression is
observed when co-delivering pMaxGFP and their corresponding siRNA of 5 pmol to
K562 cells in both commercial electroporation system and CNTPs. More GFP expression
was turned off by CNTPs, with an additional ~38% drop than that in BTX. With 30 pmol
siRNA, the downregulation of pMaxGFP plasmids by CNTPs reaches ~45% further than
that in msEP (Figure 3-4). It is worth to point out that as co-transfection of plasmids and
siRNA is used here, the delivery enhancement on the targeting reporter gene and its
corresponding siRNA occur simultaneously in CNTPs. It must turn off more proteins
than the msEP system to reach a similar protein expression level. In other words, 38% or
45% additional downregulation accomplishment comes from a much higher initial GFP
expression level for CNTP electroporation than what occurs in the msEP system.
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Figure 3-4: The Transfection efficiency of siRNA (5pmol and 30pmol) along with
pMaxGFP plasmids co-transfection of K562 cells in two different cell transfection
methods with a cell concentration of 107 cells/ml.
3.4

Conclusions

We developed a Carbon Nanotube Micropillars Electroporation system (CNTPs)
and evaluated its contributions to the delivery efficiency of DNA and RNA probes with
both adherent and suspension cells. With the Carbon Nanotube Micropillar Array
Electrodes, many cells were treated regardless of their various sizes by focus pulse
strength and the localized portion to the cell membrane. The delivery efficiency and cell
viability were evaluated with leukemia cells (i.e., K562). Although more DNA and RNA
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probes were taken up by cells under the influence of CNTPs, no significant cytotoxicity
was produced compared to the commercial electroporation system. In general, the CNTPs
showed 2~3 folds improvement on the transfection efficiency of the plasmid DNA
probes, while the cell viability shows no significant difference when compared with the
commercial electroporation system. As for the enhancement of RNA probe delivery,
there is a 2.5 folds improvement shown on the gene downregulation. According to the
results of the flow cytometer, the improvement of transfection efficiency comes from the
fact that a broad size population of cells got successfully transfected while, in the
commercial electroporation system, only certain subpopulations receives most
transfection efficiency. This success may serve as a safe and effective non-viral gene
delivery to cell samples for immunotherapy, considering its very diversified cell size and
type.

CHAPTER 4
MICROFLUIDIC ELECTROPORATION COUPLING PULSES OF
NANOSECONDS AND MILLISECONDS TO FACILITATE RAPID
UPTAKE AND ENHANCED EXPRESSION OF DNA IN CELL
THERAPY

4.1

Introduction

Electroporation works by applying short, high-voltage electrical pulses across the
cell membrane to make it transiently permeable to exogenous cargos (Gehl, 2003).
Although sub-microsecond charging time is enough to temporarily surpass the cell
membrane capacitance, the actual pulse duration in standard electroporation practice is
within sub-millisecond to millisecond range to allow effective payload delivery while
ensuring the successful recovery of the integrity of cell plasma membrane and the
survival of the treated cells. Nevertheless, owing to its balance of operation simplicity,
transfection effectiveness, and broad allowance of the probe or cell types, such reversible
electroporation systems are often chosen as the preferred delivery approach in the past
two decades to facilitate cellular internalization of plasmid DNA, oligonucleotides, and
molecule drugs in many biological and clinical studies (Sowers, 1992; Hu & Li, 2014;
Yang et al., 2019). Besides such reversible electroporation treatment, ultra-sharp, but
ultra-short electrical pulses (10 to 300 kV/cm with 10 to 300 ns pulse duration) were
recently found useful to induce cell apoptosis for cancer treatment (Beebe et al., 2002;
Garon et al., 2007; Nuccitelli et al., 2009; Perera et al., 2018; Beebe et al., 2003; Davalos
46
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et al., 2005). These nanosecond pulses are believed to alter the status of ions (e.g., Ca2+)
and biomolecules (e.g., phosphatidylserine) around cell plasma membrane or other
membrane structure of intracellular organelles, either temporarily or permanently
(Schoenbach et al., 2004; Schoenbach et al., 2001; Silve et al., 2012; Schoenbach et al.,
2001). These intracellular changes could significantly impact the signal pathways inside
cells, leading to an increase of calcium concentration within cytosol, DNA fragmentation,
caspase activation, and cell shrinkage (Vernier et al., 2003; White et al., 2004; Chen et
al., 2004). Therefore, most early studies on nanosecond pulse treatments focus on
enhancing those irreversible changes in organelles inside treated cells and their
consequent apoptosis. There are a few attempts later that look into its potential for
promotion of gene delivery since nanosecond pulses, in principle, could improve the
permeability of cell nuclear membrane (Beebe et al., 2006; Chopinet et al., 2013; Ruzgys
et al., 2018). However, owing to its ultra-short pulse duration and ineffectiveness on
breaking down the plasma membrane, disappointing gene transfection results are mostly
found unless extremely high field strength was applied in some cases (Ford et al., 2010).
However, this is often tied with low cell viability for severe side effects are associated
with the applied high electrical voltage (Pakhomoya et al., 2011; Kim et al., 2007;
Movahed & Li, 2010; Wang et al., 2009; Chang et al., 2016). DNA transfection with
nanosecond pulse treatment still faces substantial challenges to receive both desirable
gene expression and cell viability.
Speeding up nuclear delivery of plasmids is still highly desired in DNA-based
gene delivery as genetic probes were found to degrade very quickly even after cell
internalization (Lechardeur et al., 1999; Vandenbroucke et al., 2007). Unfortunately,
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available nuclear permeabilizing agents (e.g., trans-cyclohexane-1,2-diol or TCHD) are
very toxic (Griesenbach et al., 2012). Considering its potential for disrupting the nuclear
membrane structure (Tekle et al., 2005; Schoenbach et al., 2001), we hypothesize that
appropriate nanosecond pulse treatment might promote quick nuclear entry of plasmids
from cell cytoplasm while microfluidics could help suppress its associated negative
impacts on cells caused by the frequent application of high-voltage, nanosecond pulses.
Through this work, we demonstrate this concept by coupling appropriate nanosecond
pulse treatment (designated as “nsEP”) with traditional millisecond standard
electroporation (designated as “msEP”) to allow cell uptake of plasmid quickly and
efficiently. A microfluidic configuration is introduced during the nsEP treatment to
effectively mitigate the side effects induced by electrohydrolysis and Joule heating which
are commonly seen in the other nanosecond pulse treatments. In our nsEP circuit, the
nanosecond pulse generation unit is separated from the high-voltage supply unit while
linked by a MOSFET switch (Figure 4-1a). The rectangular signal from the pulse
generator periodically triggers the closure of the electroporation circuit through the
MOSFET switch to allocate high-voltage pulses with nanosecond duration. The
nanosecond pulse parameters (i.e., voltage, duration, and frequency) can be flexibly
regulated by adjusting the pulse generator signal. Two Pt wire electrodes are integrated
on the sidewall of a home-made microfluidic electroporation channel to help shorten the
response time and lower the electroporation voltage (Figure 4-1b). All these new
features together enable stable pulse voltage and a well-retained nanosecond pulse profile
when tuning some pulse parameters in nsEP treatment (Figures 4-1c & d). As some
oscillations and reflections exist at the pulse profile tail, the pulse duration mentioned in
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this work is defined as the period from the primary rectangular pulse and the followed
first spike-wave pulse, as illustrated in Figures 4-1c & d.
In this new system, nanosecond pulses are first imposed on cells to make the
nuclear membrane permeable, followed by a standard millisecond pulse treatment that
breaks down the cell plasma membrane. This allows the target DNA probes to transport
across both types of membrane barriers quickly to arrive in the nucleus. Different from
other nanosecond pulse studies with pulse durations of 60 to 300 ns (Sundararajan, 2008),
we choose slightly longer pulses (400 to 800 ns) in our nsEP treatment so that the
disruption of the nuclear membrane is more effective. Two separate pairs of electrodes
are used: one pair of platinum wire-based electrodes serve in nanosecond pulse steps and
another pair of the standard parallel-plate aluminum electrode in millisecond
electroporation treatment. Such arrangements help avoid signal entanglement between
nsEP and msEP treatment steps. The microfluidic configuration in our nsEP treatment
also helps suppress the gas bubble evolution and consequent damage to cells and/or low
cell viability that is often observed in electroporation with ultrashort pulses. The
continuous flow-through operation further allows these treatments to be done to a large
population of cells in high throughput. The new conceptual system was tested on both
CT26 (an adherent cell representative) and K562 (a suspension cell representative) cells
for DNA plasmid transfection. Demonstrated with fast kinetics and significantly
improved transgene expression without compromise of cell viability, the success of this
new electroporation system on these representative cell lines as transfection host or
cancer study models may help advance many biology studies and clinical practice on cell
function regulation and therapeutic effectiveness verification.
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4.2
4.2.1

Materials and Methods

Materials and Reagents
DNA plasmids with pMaxGFP reporter genes were purchased from Lonza, Inc.

All other cell culture reagents were purchased from Life Technologies (Carlsbad, CA),
and chemicals were purchased from Sigma-Aldrich unless specified.
4.2.2

Cell Culture
A human chronic myelogenous leukemia (CML) cell line, K562 (ATCC, CCL-

243) and a murine colorectal carcinoma cell line from a BALB/c mouse, CT26.WT cells
(ATCC, CRL 2638) were used in the electroporation experiment as the representative of
suspension cells and adherent cells, respectively. These cells were cultured in RPMI 1640
medium (supplemented with 10% FBS, 1% L-Glutamine, and Penicillin/streptomycin).
All cultures were maintained at 37 ℃ with 5% CO2 and 100% relative humidity.
4.2.3

Nanosecond Pulses Electroporation Device Fabrication
A home-made circuit board was designed to generate the nanosecond pulses with

different parameters of voltage (V), frequency (HZ), and duration (ns). The circuit board
includes three separate units, which are connected with an n-channel enhanced radio
frequency metal-oxide-semiconductor field-effect transistor (MOSFET), as shown in
Figures 4-1a. The pulse generation unit includes a low-voltage pulse generator (Agilent
33220A), a resistor load carrier, and a MOSFET switch. The power supply unit has a
high-voltage DC power supply (KIKUSUI PMC250-0.25A), two resistors, and a
capacitor (shared with the electroporation unit). The electroporation unit includes a
capacitor (shared with the power supply unit), a resistor that allocates pulse load, and the
electroporation device (either cuvette-type from standard electroporation or our home-
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made microfluidic-type one). In this nsEP circuit, the power supply pre-charges the
capacitor which is used to store energy (when the MOSFET switch is OFF) and supplies
the needed high-voltage pulses on cells (when the MOSFET switch is ON). The duration
and frequency of these pulses are decided by the rectangular pulse signal generated from
Agilent 33220A. By periodically supplying the threshold gate voltage of the MOSFET
switch, the pulse generator triggers the turn-on moment and duration of the MOSFET
switch in each pulse. The MOSFET switch manages the open and closure of the
electroporation circuit so that the pre-charged capacitor from the electroporation unit
discharges accordingly to allow the high voltage pulse to pass through the electroporation
device with designed nanosecond width and number. An oscilloscope is used to monitor
the instant nanosecond pulse profile to ensure its appropriateness. Depending on the
dimensions of the electroporation device (e.g., a gap size of a standard electroporation
cuvette or Pt wire electrode pair), proper resistors (R3 in Figure 4-1a) will be chosen in
the electroporation circuit so that its resistance is comparable to what the cell sample load
has for best electroporation performance. A microfluidic channel (500-µm wide, 300-µm
deep, and 5-cm long) was milled on a piece of poly (methyl methacrylate) or PMMA
board by a computer numeric control (CNC) machine. A piece of platinum wire (0.25
mm in diameter) was pre-embedded in the PMMA board, perpendicular to the flow
channel direction. It was then cut into two separate wire electrodes during the micromilling process with a gap size of 200 µm or longer (the actual separation distance
between the Pt electrode pair is measured after device fabrication), as shown in Figure 41b. Copper wire cables were then connected to the two Pt electrodes with the nanopulse
electroporation circuit. To monitor gas bubble issues in nsEP, the nsEP microfluidic
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device was mounted on the stage of an inverted microscope (Olympus IX71), and videos
were taken to record the gas bubble evolution at different flow rates.

Figure 4-1: Nanosecond pulse electroporation (nsEP) system. (a) The electric circuit
design; (b) the microfluidic configuration with Pt electrodes integrated on the channel
wall from both sides; (c, d) the pulse profile of individual nanosecond electric pulses at
different pulse widths (c) and pulse voltages (d).

4.2.4

Electroporation Setup and Process
Cells were first centrifuged and re-suspended in fresh OPTI-MEM I (a serum-free

medium) at a density of 1×107 cells/mL. Plasmid DNA (pMaxGFP) of 10 µg was then
added in each electroporation sample (100 µL). These samples were first loaded into the
microfluidic channel at a flow rate of 7 ml/hr to receive nsEP treatment. Nanosecond
pulses with an electrical field of ~25 to 70 kV/cm, a pulse width of 400 to 800 ns, and a
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pulse frequency of 1 to 400 kHz were applied across the two Pt wire electrodes. The cell
solution experienced the nsEP treatment was continuously collected in a traditional
electroporation cuvette downstream (with the parallel electrodes separated by 1 to 4 mm)
to receive immediate standard electroporation (550 V/cm, one 10-ms pulse with a
rectangular pulse profile). After the msEP treatment, cells were transferred to 12-well
plates and cultured for 24 hours at 37 ℃ with 5% CO2 and 100% relative humidity before
further analysis.
4.2.5

Determination of DNA Delivery Efficiency
The expression of pMaxGFP plasmids is evaluated both qualitatively by

visualizing cells with green fluorescence within some representative areas under an
inverted fluorescence microscope (Olympus, Japan) and quantitatively using flow
cytometry (CytoFLEX PN B49006AE) with a laser wavelength of 495 to 519 nm. The
results were analyzed with Cytexpert software, and 10,000 events were counted for each
sample. The transfection efficiency of pMaxGFP is defined as the number of cells
emitting fluorescence signal to the total number of counted cells in a sample (gated
fluorescence signal of GFP). The GFP expression level is quantified as the mean
fluorescence intensity of the whole counted cell population, which is correlated to the
average dosage of plasmids delivered in individual cells. Their combination reflects a
comprehensive picture of plasmid delivery and expression level in treated cells. In GFP
plasmid expression kinetics experiments, transfected cells were distributed in 24-well
culture plates and collected for flow cytometry measurements at various defined
moments (1 hr, 1.5 hrs, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, and 24 hours) post-
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transfection. In PI dye uptake experiments, 1 µl PI dye solution (1µg/µl) was added to the
cell solution (100 µl) and incubated for 20 min before further analysis or treatments.
4.2.6

Measurement of Cell Viability
MTS assays were used to evaluate cell viability. Briefly, 100 µL cells 24 hr post

electroporation from each sample were harvested from their culturing cells and
transferred to a 96-well plate. CellTiter 96 AQueous One solution (Promega, Madison,
WI) of 20 µL was added to each well, and all samples were incubated at 37 ℃ for 1 hr.
The absorbance signal of color formazan product from the reduction of MTS tetrazolium
compound by dehydrogenase enzymes in metabolically active cells is measured at 492
nm on an automated plate reader (Elx 800, Biotek, VT) to reflect the number of viable
cells present in each sample under defined conditions. The cell viability is calculated as
the absorbance signal ratio of an electroporated cell sample to what from the negative
control cell sample, after extracting the absorbance background from the media.
4.3
4.3.1

Result and Analysis

Enhancement on Reporter Gene Transfection
We hypothesize that nsEP treatment is capable of disrupting the nuclear

membrane. Therefore, a combination of nsEP and msEP treatment was carried out and
compared to an alternative treatment in which a chemical treatment using TCHD and
msEP was combined. TCHD is amphipathic alcohol that is believed to reversibly collapse
the permeability barrier of the nuclear pore complexes. It has been proven to facilitate the
nuclear entry for plasmid DNA, though very toxic to the treated cells. Our comparison
was made among three different cases: standard electroporation alone (designated as
“msEP”), TCHD treatment followed by standard electroporation (designated as
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“TCHD+msEP”), and nanosecond pulse treatment followed by standard electroporation
(designated as “nsEP+msEP”). The pulse conditions of msEP were briefly optimized and
set as one pulse of 550 V/cm for pulse strength and 10 ms for pulse duration on both
CT26 and K562 cells. The pulse conditions of nsEP were optimized on three parameters
separately: pulse voltage, pulse duration, and pulse frequency. As shown in Figure 4-2,
the best nsEP conditions with a balance of high transfection efficiency and reasonable
cell viability are also similar for these two cell lines. For most nsEP tested—unless
specified—the following nsEP conditions are adopted in the following tests: 50 kV/cm
(pulse strength), 600 ns (pulse duration), and 100 kHz (pulse frequency). Under these
pulse conditions, the “nsEP+msEP” treatment receives higher transfection efficiency and
lower toxicity in adherent cells CT26 (a model mouse fibroblast cell line for testing
immunotherapy protocols and in studies on the host immune response) when compared to
the other two treatments: the standard msEP alone and a combination of msEP with
nuclear entry promotion agent, as shown in Figure 4-3. More cells express green
fluorescence protein (GFP) for “nsEP+msEP” samples than the other two cases (Figure
4-3a). Their difference in transgene expression was further quantified by flow cytometry
measurement, with the mean GFP expression level in “nsEP+msEP” samples about three
folds and two folds higher than that in “msEP alone” and “TCHD+msEP” samples,
respectively (Figure 4-3b). This indicates that more plasmids were successfully
transfected to CT 26 cells by the “nsEP+msEP” combination treatment. The transfection
efficiency or number percentage of GFP positive cells was also measured and shown in
Figure 4-3b as follows: “nsEP+msEP” (53.5% ± 1.0%), “TCHD+msEP” (33.3±0.8%)
and “msEP alone” (24.3±0.1%). The combined “nsEP and msEP” treatment also
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demonstrates a two-fold increase in the percentage of GFP positive cells than that from
the standard electroporation treatment and 50% more than that which uses TCHD nuclear
entry promotion reagent. Unlike the “TCHD+msEP” treatment in which the cell viability
drops nearly 30% when compared to what in the “msEP alone” benchmark case, the
“nsEP+msEP” treatment does not show apparent toxicity to CT26 cells, as shown in
Figure 4-3c. The enhanced transgene expression in the “nsEP+msEP” combined
treatment is not accompanied by the sacrifice of cell viability. To demonstrate its broad
effectiveness, we also did the same treatments on a suspension cell line, K562 cells (a
chronic myeloid leukemia cell line). As shown in Figure 4-4, similar transfection
enhancement is also found on K562 cells. The standard “msEP alone” treatment receives
a cell transfection of 27.6% ± 2.6%. In contrast, the introduction of TCHD treatment
prior to msEP cell cytoplasm delivery gains a transgene expression of 45.4±2.0%, or a
~18% increase (Figure 4-4b). The “nsEP+msEP” combination treatment further
promotes the GFP expression level another ~18% more than what is achieved in the
combined “TCHD+msEP” treatment, reaching 63.1% ± 2.8% (Figure 4-4b). The mean
GFP expression level is also elevated to 1.8 times (“TCHD+msEP”) and 3.4 times
(“nsEP+msEP”) when compared with the benchmark “msEP alone” treatment. These
results prove that the combination of “nsEP+msEP” treatment more effectively enhances
transgene expression of GFP for both adherent and suspension cells than the standard
“msEP alone” or its combination with a nuclear entry promotion reagent. Different from
what happened in CT-26 cells, no significant loss of cell viability occurs for the
introduction of TCHD in K562 cells (Figure 4-4c). This may be attributed to their cancer
cell nature and robustness to TCHD treatment. Nevertheless, significant enhancement of
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plasmid transfection is achieved for the “nsEP+msEP” treatment without compromising
cell viability loss. It is more effective over not only the standard electroporation (i.e.,
“msEP”) but also many well-adopted chemical transfection approaches (Figure 4-5),
considering a balance of transgene expression and cell viability as well as the probe-tocell ratio.

Figure 4-2: The pulse condition optimization for nsEP treatment on CT 26 cells(a-c)
and K562 cells (d-f) based on a balance of transfection and cell viability. The
transfection and cell viability for nsEP with pulses of different electric voltages (0.51.4kV) under a fixed pulse frequency (100 kHz) and duration (600 ns) (a, c), different
pulse duration (400-800 ns) under a fixed pulse voltage (1.0 kV) and frequency (100
kHz) (b, e), and different frequencies (1 to 400 kHz) under a fixed pulse duration (600
ns) and voltage (1.0 kV).
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Figure 4-3: The transfection and cell viability of CT26 cells 24 hrs after transfection in
three different cell transfection methods with a cell concentration of 107 cells/mL. (a)
The phase-contrast (left) and fluorescent (right) images of cells treated by each
method; (b) quantitative transgene expression presented both by transfection efficiency
as the number percentage of GFP positive cells (data on the left group) and mean
fluorescence intensity for average GFP dosage in individual cells (data on the right
group, readings were divided by a factor of 105); (c) cell viability by MTS assays for
cells treated by each method. In panels b and c, “msEP alone”: columns with green,
upward diagonal stripes; “msEP+TCHD”: columns with orange, horizontal stripes;
“nsEP+msEP”: columns with blue downward diagonal stripes. Significance t-test was
performed with comparison to “msEP alone” treatment (n=3) with **P < 0.01 and ***
P < 0.005.
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Figure 4-4: The transfection and cell viability of K562 cells 24 hrs after transfection in
three different cell transfection methods with a cell concentration of 107 cells/mL. (a)
The phase-contrast (left) and fluorescent (right) images of cells treated by each
method; (b) quantitative transgene expression presented both as transfection efficiency
for the number percentage of GFP positive cells (data on the left group) and mean
fluorescence intensity for average GFP dosage in individual cells (data on the right
group, readings were divided by a factor of 105); (c) cell viability by MTS assays for
cells treated by each method. In panels b and c, “msEP alone”: columns with green,
upward diagonal stripes; “msEP+TCHD”: columns with orange, horizontal stripes;
“nsEP+msEP”: columns with blue downward diagonal stripes. Significance t-test was
performed with comparison to “msEP alone” treatment (n=3) with **P < 0.01 and ***
P < 0.005.
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Figure 4-5: Comparison of transfection performance of “nsEP+msEP.” electroporation
treatment with other standard transfection methods in K562 cells. Standard
electroporation is the same as the case designated as “msEP alone” in this paper;
“polyplex (N/P=6.7)” represents polyplex transfection cases with samples prepared by
vortex mixing polyethyleneimine (PEI, branched with MW=25K from Sigma-Aldrich)
and pmaxGFP plasmid at an N/P ratio of 6.7 (the molar ratio of positively charged
amine groups on PEI with negatively charged phosphate groups on DNA); “lipo2000
(protocol)” represents lipofectamine 2000 (from Life Technologies) transfection cases
following the vendor’s protocol (1 µg plasmid, 2 µL lipofectamine 2000 for 4 × 104
cells); “lipo2000 (scale-up)” represents lipofectamine 2000 transfection cases having
probe dosage scaled up according to theµ cell numbers that are used in our
electroporation treatment (25 µg plasmid, 50 µL lipofectamine 2000 for 1 × 106 cells).
The transfection is shown as mean fluorescence intensity measurement by flow
cytometry (columns on the right-side group), and the cell viability is quantified via
MTS assay (columns on the left side group), with three independent experiments.
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4.3.2

Enhancement on Transgene Expression Kinetics
As we hypothesized, nsEP treatment has advantages on cell nuclear membrane

disruption, the transgene expression time should be significantly shortened for plasmid
DNA probes with the permeable nuclear membrane and quick nuclear transport. To
verify this hypothesis, we measured both the uptake of propidium iodide (PI) dye and
expression kinetics the GFP plasmids using flow cytometry. As shown in Figure 4-6a,
the uptake of PI dyes reaches 97.2% after the “nsEP+msEP” combination treatment. In
contrast, the “msEP alone” treatment gets only 13.6%, which is only slightly higher than
the case for merely incubating PI dyes with the cell solution (10.3%). Considering the
membrane-impermeant nature of PI dyes and the fact that fluorescence signal emits only
if PI dye molecules intercalate into the major groves of double-stranded DNA molecules,
these results indicate that msEP alone cannot effectively disrupt the integrity of cell
nuclear membrane, though the permeable cell membrane after msEP allows PI dyes to
arrive in the cell cytosol. With additional nsEP treatment (i.e., for “nsEP+msEP” case),
the dramatic increase of the fluorescence signal confirms that both the plasma membrane
and the nuclear membrane of cells are successfully broken down to allow PI dyes to flush
in and migrate all the way to the cell nucleus to conjugate with DNA molecules for
fluorescence emission. To further prove the effectiveness of nsEP treatment on nuclear
delivery, the expression kinetics of GFP plasmids in K562 cells is also monitored by
measuring the DNA expression level at various moments of the first 24 hours after the
“nsEP+msEP” combination treatment. The enhancement of the green fluorescent signal
from GFP proteins was detected as early as 1.5 hours post-treatment, as shown in Figure
4-6b. By 6 hours, the GFP expression level in the “nsEP+msEP” samples is almost the
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same as what in the “msEP alone” treatment 24 hours post-transfection. From these
results, we conclude that the contribution of nsEP towards the enhancement of
transfection rate is likely the result of fast and massive transport of DNA plasmid across
the cell nuclear membrane, so that early and efficient transcription process is initiated.

Figure 4-6: (a) The PI dye uptake and (b) transgene expression kinetics of GFP
plasmid in K562 cells for nsEP+msEP combination and msEP alone treatments. The
nsEP conditions: 50 kV/cm (pulse strength), 100 kHz (pulse frequency), and 600 ns
(pulse duration) and the msEP condition: 550 V/cm (pulse strength), one pulse, and 10
ms (pulse duration). In panel b, “msEP alone”: columns with green, upward diagonal
stripes; nsEP+msEP: columns with blue downward diagonal stripes.
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4.3.3

Importance on The Treatment Order of nsEP and msEP
Although nsEP helps make the nuclear membrane more permeable, significant

enhancement of gene expression would not be achieved if the efficient crossing of the
cell plasma membrane does not occur. We learned this from our early failed experimental
efforts. In some of those early-stage experiments, the nsEP treatment was done alone
under the same pulse conditions, but no successful plasmid transfection was found. This
suggests that nanosecond pulses alone cannot make cell membrane permeable enough to
allow effective cell uptake of plasmid DNA. In another set of experiments in which the
msEP treatment was delayed one hour after the completion of nsEP treatment, we found
the transgene expression enhancement effect also disappeared. These results suggest that
without the quick introduction of plasmid DNA in the cell cytosol, the disrupted nuclear
membrane might recover its integration before DNA molecules arrive there so that the
nsEP treatment, which has the benefit of nuclear permeability enhancement, would be
done in vain. In a different case, we switched the execution order of the nsEP and msEP
treatment combination. When msEP is done before nsEP in the combined treatment
(designated as “msEP+nsEP”), the transgene expression of GFP is not as high as its
opposite combination order (“nsEP+msEP). As shown in Figures 4-7a & b, the GFP
expression for the “msEP+nsEP” treatment receives a transfection efficiency of
51.4±3.6%, about 12% lower than what with the combination order as “nsEP+msEP”
(63.1% ±2.8%) at the same pulse conditions. Moreover, the cell viability of the
“msEP+nsEP” treatment also drops about 10% when compared to what in the
“nsEP+msEP” cases (Figure 4-7c). This suggests that having already disrupted cell
membranes makes further polarization of cell nuclear membranes less effective. The
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followed high-frequency nanosecond pulses cause more loss of ions or molecules from
the treated cells than what happened in the “msEP alone” treatment. Their damage to
cells is so severe that the promotion to the nuclear delivery of DNA is mostly offset by
the slow recovery of the cellular membrane and some metabolic functions of the treated
cells, resulting in their low survival rate. This is probably one primary reason that
undesired low transfection efficiency and/or cell viability were received in other
nanosecond pulse treatments (Chopinet et al., 2013).
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Figure 4-7: The effect of the combination order of msEP and nsEP on DNA delivery:
(a, b) transfection efficiency and (c) cell viability. In panels b & c, “msEP alone”:
columns with green, upward diagonal stripes; “msEP+nsEP”: columns with cyan,
vertical stripes; “nsEP+msEP”: columns with blue downward diagonal stripes.
Significance t-test was performed with n=3 and ** represents P < 0.01 and *** for P<
0.005 with comparison made to “msEP alone” treatments.
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4.3.4

Contribution of Microfluidics on Electroporation Enhancement
The introduction of microfluidics during nsEP enables close patterning of Pt

electrodes so that a low pulse voltage is sufficient to meet the required field strength for
effective nanosecond treatment, besides its additional benefit of high throughput on cell
processing. More importantly, we found a microfluidics configuration helps suppress the
gas bubble evolution and Joule heating issues that often lead to low cell viability during
nanosecond pulse treatment. As shown in Figures 4-8a & b, no visible gas bubbles are
found near the electrodes with a 100  magnification at the regular flow rate in our nsEP
treatment (7 ml/hr). However, if the cell flow is slowed down, gas bubbles are clearly
observed to appear continuously near the electrode surface when the nanosecond pulse
signal is turned on (Figures 4-8c - 4-8f). The generated gas bubbles grow quickly on the
electrode surface while they are eventually taken away by flow downstream when getting
too big. The slower the liquid flow, the bigger the gas bubbles are. This suggests that the
suppression of electrohydrolysis and Joule heating phenomena by this microfluidic nsEP
system comes from the quick takeaway of bubbles from their generation spots (the Pt
electrodes) so that the associated gas bubble evolution issues are minimized. As a result,
high cell viability and better enhancement of transgene expression (i.e., more transfected
cells survived the electroporation treatment with normal metabolism) are achieved
simultaneously with this microfluidic “nsEP+msEP” treatment.
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Figure 4-8: Gas bubble formation and evolution dynamics in microfluidic nsEP
treatment at various flow rates. Photos of microfluidic device without nsEP treatment
(a) and with nsEP treatment of a K562 cell solution flowing at 7 ml/hr (b), 6 ml/hr (c),
5 ml/hr (d), 3 ml/hr (e), and 0 ml/hr (f). The scale bars represent 100 µm. (Note: texture
shown in the channel region of each image comes from winkles of scotch tape sealing
the microfluidic channel).
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4.4

Discussions

The generation of electric pulses with both high-voltage field strength and a
mixture duration of a millisecond and nanosecond duration is not trivial. Severe signal
entanglement and profile distortion often occur. Two design features are applied in our
system to avoid these issues. First, we separate the nanosecond pulse generator and highvoltage supply units into two different electric circuits, which are bridged by a MOSFET
switch. The frequency (Hz) and duration (ns) of the nanosecond pulses are decided by the
pulse signal generator while the high voltage electric field imposed on cells is supplied by
the pre-charged capacitor through the high voltage supply circuit. The decoupling of the
pulse voltage and duration (and frequency) in our nsEP treatment helps maintain an
appropriate pulse profile when some other pulse parameters are changed. Together with
the Pt wire electrode pair, nanosecond pulses in our nsEP system have ultra-short
responding time, well-defined signal profile, and stable pulse voltage. For example, when
the pulse width or amplitude is changed, the waveform (amplitude or width) of those
nanosecond pulses, including the primary rectangular part and the reflection tail, is well
retained. Another design we adopted to avoid signal entanglement lies in the separation
of the nsEP and msEP treatments with different devices. A microfluidics-based nsEP
treatment is followed by a cuvette-based standard msEP electroporation. Such
configuration separation allows the complete decoupling of the two types of pulse signals
in nsEP and msEP treatments. The pulse conditions for each treatment can be tuned
separately without interactions from the other, making the comparison and optimization
of electroporation protocols easier and more reliable.
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Besides quick responding time, the proximity placement of the two Pt wire electrodes on
the sidewall of the microfluidic channel further allows relatively low applied voltage or
energy dose and long pulse duration in our nsEP treatment. This helps to collapse the
nuclear membrane more effectively without much cell toxicity, unlike what is observed
in irreversible electroporation with ultrashort pulses. Moreover, the introduction of a
microfluidic configuration in the nsEP treatment mitigates electrohydrolysis-induced side
effects such as gas bubble evolution and Joule heating, another significant negative
impact of other nanosecond pulse treatment on permanent damage to cells and/or
consequent cell apoptosis. Gas bubble formation is normal in electroporation, contributed
by water electrohydrolysis. With the presence of gas bubbles, they disturb the
instantaneous local electric field, making the followed pulse disruption on neighbor cells
much less effective. Moreover, the accompanied Joule heating further elicits the bubble’s
growing, rising, and bursting (Kim et al., 2007). Since many cells are trapped around gas
bubbles, such bubble evolution dynamics causes further detrimental damage to cells,
varying from the impact on cell physiological response to complete cell lysis. In our
microfluidic nsEP treatment step, gas bubbles were generated on the electrode surface,
like in most studies employing electroporation. However, the generated gas bubbles were
quickly taken downstream by flow, away from the Joule heating source (i.e., near Pt
electrodes) before growing too big. Such suppression of gas bubble evolution is one key
to the success of this microfluidic “nsEP+msEP” combination treatment. Similar gas
bubble evolution dynamics were also found in our early studies on cuvette based standard
msEP treatment (Wang et al., 2009). With still fluid in a cuvette that stands straight up,
gas bubbles are generated, further grow, rise, aggregate, and burst when arriving at the
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air-liquid interface. Strong convection of liquid caused by gas bubble dynamics during
pulsation period not only traps and damages cells (particularly when burst) but also
dramatically affects the local electric field of the followed pulses. Although the gas
bubble issues vary with the pulse conditions such as pulse type, strength, and duration, it
is probably another cause of the disappointing transgene expression outcomes in some
early nanosecond pulse studies employing cuvettes in their entire treatments (Chopinet et
al., 2013). As this issue is primarily suppressed in this microfluidic “nsEP+msEP”
treatment, it is not surprising that better enhancement of transgene expression and high
cell viability are achieved simultaneously.
4.5

Conclusions

In summary, we developed a new microfluidic electroporation approach with a
combination of nanosecond and millisecond pulses to enhance plasmid DNA transfection
without sacrifice on cell viability. For adherent cells CT26 and suspension cells K562,
transgene expression of GFP plasmid is more than doubled at the same cell viability
levels as in standard msEP electroporation. Promotion on nuclear entry by nanosecond
pulses and the suppression of gas bubbles with the microfluidic operation is believed to
be the two major contributions by this new system on the transfection enhancement.
Having nsEP first and msEP followed immediately is found to work more effectively
than other cases with either the opposite operation order or having a long waiting period
between the two types of pulse treatments. This new microfluidic nsEP and msEP
combination treatment not only facilitates plasmid delivery and expression but also
eliminates the electrohydrolysis-induced apoptosis and low cell viability issues
commonly tied with nanosecond pulse treatments. Its success may benefit many biology
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studies and clinical practice in understanding gene functions, controlling cellular signals,
screening drugs, and applying cell-based therapeutic technologies.
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CHAPTER 5
COUPLING NANOSECONDS ELECTROPORATION AND CARBON
NANOTUBE MICROPILLAR ELECTROPORATION ENHANCED
GENE PROBES DELIVERY IN WHOLE BLOOD THERAPY

5.1

Introduction

As a new and proven method, immunotherapy has gradually been recognized by
the cancer treatment community (Khalil et al., 2016). It activates or stimulates the
patient’s immune system to allow better recognize tumor antigens or specific aggregation
and/or attack tumor cells (Davis, 2000; Oiseth & Aziz, 2017). However, in current
immunotherapy treatments, only some specific types of cells, such as T cell or DC, can
be treated. Besides their low transfection efficiency, the treated cells have a low survival
rate and further, in vitro expansion, the cell population is often needed. Therefore, a
general immunotherapy method includes performing lymphatic injection on the patient or
isolate the patient’s blood to extract specific lymphocytes first. The collect cell samples
are then received in vitro transduction using viral vectors. After further cell expansion,
the mature cells are eventually injected back to the patient to conduct immunotherapy.
With two unavoidable surgery involvements, this approach always causes significant and
long-term pain for patients.
To solve this problem, we coupled our nanoseconds electroporation and carbon
nanotube micropillars electroporation configuration (nsEP+CNTPs), two newly
72
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implemented electroporation technologies demonstrated in chapters 3 and 4, to treat
primary T lymphocytes and whole blood samples in this chapter. Due to its quick
completion of electroporation treatment (within seconds), the cell transfection step can be
done in the first sampling step and the second surgery is therefore avoided. Specifically,
we first use nanosecond pulse electroporation to pre-treat the primary blood cells to
weaken the integration of their cell membrane and more important to create pores on the
nuclear membrane. Then millisecond pulses via Carbon Nanotube Micropillars
Electroporation are applied to homogeneously treat cells of various types and sizes.
Primary red blood cells and T cells were transfected separately with the same pulse
conditions using GFP encoding plasmids or mRNA with therapeutic genes to complete
the optimization. Because of the limited primary T cell supply and the huge cell
population difference of erythrocytes, reticulocytes, and leukocytes in whole blood
samples, we simplified our treatment by using a mixture of normal blood cell samples
(most are red blood cells) and K562 cells to simulate different situations and test potential
interference of transfection performance for samples with different populations of red
cells and immune cells. Because of the no-nucleus fact of mature red blood cells,
microRNA miR-29b was used as the presenting probe to evaluate the electroporation
transfection efficiency in red blood cells. After transfection, the therapeutic functions of
miR-29b in our model blood cells post-transfection can be conveniently monitored by
measuring some targeting protein levels in K562 cells this microRNA (miRNA) probe
commonly regulates.
Among different oligonucleotides, miRNA is a small non-coding single-stranded
small-molecule RNA with a length of about 20 to 25 nucleotides (a few are less than 20

74
nucleotides). Many studies have shown that miRNA can inhibit target mRNA translation
or induce shear through specific base pairs (Lee et al., 1993). Thereby down-regulating
gene expression at the post-transcriptional level, promoting rapid deadenylating of target
mRNA, and making it easy to degrade are among the primary mechanisms for miRNA
inhibition on gene expression (Wu et al., 2006). Among different therapeutic miRNA,
miR-29b can regulate tumor cell proliferation, differentiation, apoptosis, invasion,
metastasis, and drug resistance in several pathways (Jiang et al., 2014; Alizadeh et al.,
2019). It can directly target on DNMT3B gene to inhibit the process of DNA
methylation, thereby alleviating tumorigenesis. It can also bind to the CDK6 gene, so that
the cell cycle is trapped in the G1 phase, thereby inhibiting the proliferation of tumor
cells. It can also target on MCL-1 gene and inhibit its expression, thereby promoting
cancer cells to apoptosis. Therefore, we evaluated the expression level of CDK6,
DNMT3b, and MCL-1in K562 cells to confirm the downregulation function of miR-29b
probes that being loaded in blood samples.
In this chapter, GFP mRNA transfection efficiency was first tested on primary T
cells obtained from the spleen. The transfection efficiency enhancement of nsEP+CNTPs
in red blood cells was then evaluated using microRNA. After that, a mixture of primary
red blood cells and K562 lymphoblast in different ratios were evaluated for both DNA
plasmids and microRNA transfection efficiency. And at last, the reservation of the
therapeutic functions of the delivered probes was evaluated by measuring the expression
efficiency of miR-29b target genes (CDK6, DNMT3b, and MCL-1) in leukemia cells.
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5.2
5.2.1

Materials and Methods

Materials and Reagents
GFP mRNA was synthesized from pGEM4Z/GFP/A64 DNA plasmids template

with a T7 mScript Standard mRNA Production System, purchased from CellScript,
Madison, WI, USA. DNA plasmids probe with pMaxGFP reporter genes were purchased
from Lonza, Inc. The miRIDIAN microRNA human has-miR-29b-3p mimic with miR
sequence: 5-UAGCACCAUUUGAAAUCAGUGUU-3 was purchased from Thermo
Scientific (Pittsburgh, PA). All other cell culture reagents were purchased from Life
Technologies (Carlsbad, CA), and all the chemicals were purchased from Sigma-Aldrich
unless specified.
5.2.2

Cell Culture
Primary CD8+ T cells were isolated from the spleens under aseptic conditions.

Individual spleens were homogenized to release splenocytes, in 5 ml RPMI 1640
medium. A human chronic myelogenous leukemia (CML) cell line, K562 Cells (ATCC,
CCL-243) and beef cattle whole blood (obtained from Louisiana Tech University, School
of Agricultural Sciences & Forestry) were used in the electroporation test. These cells
were cultured in RPMI 1640 medium (supplemented with 10% FBS, 1% L-Glutamine,
and Penicillin/streptomycin). All cultures were maintained at 37 ℃ with 5% CO2 and
100% relative humidity.
5.2.3

Electroporation Setup and Process
Cells were first centrifuged and re-suspended in fresh OPTI-MEM I (a serum-free

medium) at a density of 1 × 106 cells/mL. Plasmid DNA (pMaxGFP) of 10 µg or
microRNA probes (has-miR-29b) of 100 pmol were then added in each electroporation
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sample (100 µL). These samples were first loaded into the microfluidic channel at a flow
rate of 7 ml/hr to receive nsEP treatment. Nanosecond pulses with an electrical field of
~15 kV/cm, a pulse width of 600 ns, and a pulse frequency of 100 kHz were applied
across the two Pt wire electrodes. The cell solution experienced the nsEP treatment was
continuously collected and loaded onto the CNTPs surface (CNTPs was considered as a
positive electrode). A piece of ITO-coated Glass (ITO Coated Glass was considered as a
negative electrode) with a PDMS gasket (~200 µm thickness) was covered onto the cell
solution sample. Electric pulse was added onto these samples (2.5 kV/cm, single 10-ms
pulse with a rectangular pulse profile). After the electric pulse, the ITO-coated Glass was
removed from CNTPs. Cells were collected and transferred to 12-well plates and cultured
for 24 hours at 37 ℃ with 5% CO2 and 100% relative humidity prior to further analysis.
5.2.4

Determination of DNA Delivery Efficiency
The expression of pMaxGFP plasmids is evaluated both qualitatively by

visualizing cells with green fluorescence within some representative areas under an
inverted fluorescence microscope (Olympus, Japan) and quantitatively using flow
cytometry (CytoFLEX PN B49006AE) with a laser wavelength of 495 to 519 nm. The
results were analyzed with Cytexpert software, and 10,000 events were counted for each
sample. The transfection efficiency of pMaxGFP is defined as the number of cells
emitting fluorescence signal to the total number of counted cells in a sample (gated
fluorescence signal of GFP). The GFP expression level is quantified as the mean
fluorescence intensity of the whole counted cell population, which is correlated to the
average dosage of plasmids delivered in individual cells. Their combination reflects a
comprehensive picture of plasmid delivery and expression level in treated cells.
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5.2.5

Determination of microRNA Delivery Efficiency
The miR-29b delivery efficiency was evaluated by the expression level of miR-

29b. To measure expression levels, the total RNA was first reverse transcription into
cDNA, and a Realtime-PCR was conducted. The expression level was determined by the
ΔΔCt method and normalized to endogenous controls.
5.2.6

Total RNA Extraction
Total RNA was extracted using TRIzol reagent (Life Technologies, Carlsbad,

CA). Cells were harvested by centrifugation, and the culture medium was removed. And
250 µl TRIzol reagent was added to each sample (containing approximately 8 to 10 x 105
cells). Samples were lysed by pipetting several times and incubated for 5 min at room
temperature. The nucleoprotein complex was dissociated completely. 125 µl chloroform
was added to each sample, and the tubes were shaken vigorously for 15 s followed by 3
min incubation at room temperature. Then all the samples were centrifuged with 12,000
rpm for 15 min at 4 ℃ and all the samples were separated into a colorless upper aqueous
phase, interphase, and a lower red chloroform phase. The upper aqueous phase was
transferred into new tubes by gentle pipetting without drawing any of the interphases, and
500 µl 100% isopropanol was added into each of aqueous phase tubes, followed by 10
min incubation at room temperature. The samples were centrifuged at 12,000 rpm for 10
min at 4 ℃. And the supernatant was removed. To wash the RNA pellet, 200 µl 75%
ethanol was added into each tube. Samples were vortexed briefly and centrifuged at 7500
rpm for 5 min at 4 ℃. The supernatant was removed. The RNA pellets were air-dried for
5 to 10 min. 20µl RNase-free water was added into each tube, and all the samples were
incubated at 60 ℃ for 10 min. Then the RNA was ready for downstream application.
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5.2.7

Reverse Transcription PCR
The Taqman® microRNA Reverse Transcription Kit (Life Technologies,

Carlsbad, CA) was used for microRNAs reverse transcription. The reagents were first
allowed to thaw on ice. The total volume of 15 µl reaction was prepared in a
polypropylene tube, including 0.15 µl dNTP mix (100 mM total), 1 µl MultiscribeTM RT
enzyme (50 U/µl), 1.5 µl 10X RT PCR buffer, 0.19 µl RNase inhibitor (20 U/µl), 4.16 µl
nuclease-free water, 3 µl primer and 5 µl RNA sample (~1000 ng). the thermal cycler
was programmed as follows: 30 min at 16 ℃, 30 min at 42 ℃, 5 min at 85 ℃ and hold at
4°C.
5.2.8

qRT-PCR Amplification
The resulting cDNA from reverse transcription reaction was amplified by qRT-

PCR with TaqMan™ Gene Expression Master Mix (Thermo Scientific, Pittsburgh, PA).
The total volume of 20 µl reaction was prepared in a polypropylene tube, including 10 µl
TaqMan™ Gene Expression Master Mix, 1 µl 20 X TaqMan® assay and 9 µl cDNA
template. The thermal cycler was programmed as follows: 10 min at 95 ℃ for
polymerase activation, then 40 PCR cycles with 15 seconds at 95 ℃ for denaturing and 1
min at 60 ℃ for annealing. The relative gene expression was determined by the ΔΔCt
method. The mature miR-29b expression was normalized to endogenous control RNU48
and relative to the untreated control cells. The expression of CDK6, DNMT3B, and
MCL-1 mRNAs was normalized to endogenous controlled GAPDH and relative to the
untreated controlled cells.
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5.3
5.3.1

Results and Discussion

Enhanced mRNA Transfection in Primary T Cells
To demonstrate the enhancement of Nanosecond Pulses electroporation coupling

Carbon Nanotube Micropillars Electroporation (nsEP+CNTPs) on transfection efficiency
for the whole blood immunotherapy, we need to demonstrate the genetic probes
transfection efficiency enhancement on leukocytes first as they are the primary target in
immunotherapy. However, since the proportion of leukocytes in whole blood cells is very
limited (less than 5%), we chose to isolate the primary T cells from the whole blood for a
separate test first. The transfection enhancement was demonstrated with the GFP mRNA
probe (in vitro transcript from pGEM4Z/GFP/A64 GFP DNA plasmids). We
electroporated 1 × 107 primary T cells with 5 µg of GFP mRNA with nsEP+CNTPs and
commercial electroporation device (BTX). Transfection efficiency was measured by flow
cytometer after 24 hrs. As shown in Figure 5-1 (a), the transfection efficiency with the
nsEP+CNTPs system (6.1% for primary T cells) is generally better than that from BTX
(1.2%). Although the overall efficiency is not very high, for primary T cells, the
transfection efficiency brought by the new coupling electroporation system is already ~5
folds multiple of the commercial electroporation device (BTX). These results confirm
that the enhancement of the nsEP+CNTPs system on mRNA transfection for primary T
cells. This result was compared to the transfection efficiency promotion of the
nsEP+CNTPs electroporation system on K562 lymphoblast. In that experiment, 1 × 107
K562 cells with 10 µg of GFP plasmids were electroporated by nsEP+CNTPs and
commercial electroporation device (BTX). Transfection efficiency was measured by flow
cytometer after 24 hrs. As shown in Figure 5-1 (b), the standard “BTX” treatment

80
receives a cell transfection of 24.2% ± 3.6%. In contrast, the nsEP+CNTPs treatment
gains a transgene expression of 72.4±6.3%, or a ~ 3 folds increase. These results show
similar effectiveness of this nsEP+CNTPs electroporation system on genetic probe
transfection. Considering their similar cell size and electrical properties as well as similar
transfection performance, we added K562 lymphoblast in blood cell samples as model
blood cell mixture in later transfection experiments to enhance the result statistics of
leukocyte transfection given the limited primary T cell resource.

Figure 5-1: Result for nsEP + CNTPs & BTX enhanced GFP mRNA/GFP DNA
Plasmids delivery in primary T cells (a) and K562 lymphoblast (b).
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5.3.2

Enhanced microRNA Probes Transfection in Red Blood Cells and

Lymphoblast
To demonstrate the gene delivery enhancement function of our device in the
whole blood, we used microRNA as our genetic test probe (miR-29b). This comes from
the fact that more than 90% of whole blood cells are red blood cells. Without a nucleus,
red blood cells cannot replicate and transcribe DNA probes, so DNA plasmids were not
used in this experiment. Also, because microRNA and mRNA used in immunotherapy
are similar in molecular components, we used microRNA as our genetic probes here. In
this experiment, we used the same electroporation condition on both red blood cells and
K562 cells as we did in primary T cells without further optimization to mimic closely the
treatment conditions in future whole blood immunotherapy. Compared to the commercial
electroporation system, the mature miR-29b expression increased ~2.5 folds in the K562
lymphoblast cells and ~3 folds in the whole blood cells at 24 hours after electroporation.
This increase demonstrates that the nsEP+CNTPs device had enhanced miR-29b
expression in both Red blood cells and lymphoblast (Figure 5-2).
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Figure 5-2: Result for nsEP + CNTPs & BTX enhanced miR-29b delivery in Red
blood Cells (a) and K562 cells (b).

5.3.3

Enhanced DNA Plasmids Probes Transfection in Blood Cell Mixture
To evaluate DNA plasmid delivery efficiency enhancement in blood cell samples

at different ratios, we set three model samples in the following proportions: 50% whole
blood cells and 50% K562 Cells; 80% whole Blood Cells and 20% K562 Cells; 90%
whole Blood Cells and 10% K562 Cells, and the total cell number is 1 million per each
sample. We electroporated these samples with 10 µg of pMaxGFP plasmids with
nsEP+CNTPs and BTX. Transfection efficiency was measured by flow cytometer after
24 hrs. Because red blood cells do not have a nucleus and cannot transcribe the plasmids,
the expression of GFP mainly comes from K562 cells and the small portion of leukocytes
in blood samples. The purpose of mixing red blood cells here is to test the leukocytes
(K562 cells were added here to increase the represented percentage of leukocytes) uptake
efficiency of DNA plasmids under the interference of many small red blood cells. This
helps estimate the interference of the large presence of red blood cells to the electric field
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and the leukocyte uptake of plasmids. As shown in Figure 5-3 and Figure 5-4, compared
to BTX method, the pMaxGFP plasmids transfection efficiency is ~1.8 folds when the
cell type ratio is 50% whole Blood Cells and 50% K562 Cells, ~1.6 folds when the cells
type ratio is 80% whole Blood Cells and 20% K562 Cells, and ~2.4 folds when the cells
type ratio is 90% whole Blood Cells and 10% K562 Cells in those the cells that were
electroporated with nsEP+CNTPs at 24 hours after electroporation (Figure 5-5). The
transfection efficiency of K562 electroporated alone is a little higher than the cell mixture
samples. This result indicates that in the complex blood environment, under the
interference of red blood cells, the nsEP+CNTPs electroporation transfection efficiency is
still higher than the traditional electroporation method and the presence of a large
population of red blood cells does not affect significantly the transfection performance.
This proves that the nsEP+CNTPs has great prospects for electroporation of blood in
immunotherapy.
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Figure 5-3: The Flow Cytometry Analysis Results of three Blood Model samples: 50%
Whole Blood Cells and 50% K562 Cells; 80% Whole Blood Cells and 20% K562 Cells;
90% Whole Blood Cells and 10% K562 Cells. They were electroporated by the BTX
method.
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Figure 5-4: The Flow Cytometry Analysis Results of three Blood Model samples: 50%
Whole Blood Cells and 50% K562 Cells; 80% Whole Blood Cells and 20% K562
Cells; 90% Whole Blood Cells and 10% K562 Cells. They were electroporated by
nsEP + CNTPs method.
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Figure 5-5: DNA plasmids transfection efficiency result for nsEP + CNTPs & BTX in
different cells ratio models.
5.3.4

Enhanced microRNA Probes Transfection in different Red Blood/

Lymphoblast Cells ratio
To test the microRNA delivery efficiency of cells in different sizes and types, we
mixed red blood cells and K562 cells at different ratios. In this section, we set three
model samples in the following proportions: 50% whole Blood Cells and 50% K562
Cells; 80% whole Blood Cells and 20% K562 Cells; 90% whole Blood Cells and 10%
K562 Cells. This is to simulate the complex cellular environment. Electroporation was
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applied to these three samples with 100 pmol miR-29b by nsEP+CNTPs device and
traditional electroporation device (BTX). Mature miR-29b transfection efficiency was
determined in these three samples. As shown in Figure 5-6, compared to the benchmark
of commercial electroporation treatment, the mature miR-29b expression was increased
~1.6 folds when the cell type ratio is 50% whole Blood Cells and 50% K562 Cells, ~2.2
folds when the cells type ratio is 80% whole Blood Cells and 20% K562 Cells, and ~2.3
folds when the cells type ratio is 90% whole Blood Cells and 10% K562 Cells in those
the cells that were electroporated with nsEP+CNTPs at 24 hours after electroporation.
This increase demonstrated that the nsEP+CNTPs device had enhanced miR-29b
expression when there are different cell types or sizes. This result indicates that when the
cell size varies greatly, the commercial electroporation device cannot function well, while
the nsEP+CNTPs device can still contribute significant enhancement.
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Figure 5-6: Mature miR-29b Expression in different Whole Blood Cells and K562
Cells ratio models. 50% Whole Blood Cells and 50% K562 Cells; 80% Whole Blood
Cells and 20% K562 Cells; 90% Whole Blood Cells and 10% K562 Cells.

5.3.5

Enhaced microRNA Probes Down-Regulation Function Efficiency in

Lymphoblast Cells
To further demonstrate the function reservation of the delivered miR-29b
microRNA, we also tested the down-regulation efficiency of miR-29b targeting genes.
Similarly, because red blood cells have no nuclei, the downregulation of those target
protein levels is only contributed by K562 cells. As shown in Figure 5-7, for cells that
were electroporated by nsEP+CNTPs, the target genes DNMT3B, MCL-1 and CDK6
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were downregulated by ~60%, ~50%, and ~60%, respectively, compared to the cells that
were electroporated by the commercial electroporation system, in which the target genes
DNMT3B, MCL-1, and CDK6 were down-regulated by ~40%, ~15%, and ~45%,
respectively. The expression of targeted genes was more efficiently downregulated in
cells electroporated by nsEP+CNTPs compared to by commercial electroporation system.

Figure 5-7: Result for nsEP + CNTPs & BTX enhanced the downregulation of
targeting genes in K562 cells.

5.4

Conclusions

This chapter focuses on the mRNA, DNA plasmids, and microRNA delivery with
the nsEP+CNTPs electroporation method in primary T cells and whole blood samples.
CNTPs were used to enhance the strength of the local electric field for different types and
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sizes cells and conjugated with the Nanosecond pulses to enhance the genetic probe
delivery efficiency. The genetic probes release, expression, and function on target genes
were evaluated. Based on the higher expression efficiency of the nsEP+CNTPs, we
concluded that this method performs better than the traditional electroporation method in
whole blood cells. Since DNA/RNA based vaccines therapy is a very important treatment
method in immunotherapy, the nsEP+CNTPs method provides a favorable prospect for
non-viral gene delivery-based immunotherapy. We also expect that this new type of
electroporation method can eventually be applied to whole blood immunotherapy.

CHAPTER 6
CONCLUSIONS AND FUTURE WORK

6.1

Conclusions

Electroporation is a practical non-viral cell transfection approach for its balance
on the transfection efficiency and cell viability, no restrictions of the probe or cell type,
and operation simplicity. In this dissertation, we investigated the improvement of
electroporation performance through the introduction of carbon nanotube micropillars
electroporation and nanosecond pulses electroporation. Results are concluded as follows:
With the application of carbon nanotube micropillars electroporation, we
demonstrated better DNA, siRNA and microRNA delivery efficiency in mammalian cell
electroporation, and some loss on the cell viability, but not statistically significant. By
apply carbon nanotube micropillars electroporation, we observed that all size cells could
be uniformly electroporation, but not only the middle size cells. The delivery efficiency
and cell viability were evaluated with both adherent cells (i.e., CT-26) and suspension
cells (i.e., K562). Although more DNA and RNA probes were taken up by cells under the
influence of CNTPs, no significant cytotoxicity was produced compared to the
commercial electroporation system. In general, the CNTPs showed 2 to 3 folds
improvement on the transfection efficiency of the plasmid DNA probes while the cell
viability showed no significant difference compared with the commercial electroporation
system. As for the enhancement of the RNA probes delivery, there was a 2.5 folds
91
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improvement showed from the gene downregulation. According to the results of the flow
cytometer, the improvement of transfection efficiency is mainly due to the larger size or
smaller size cells got transfected, in which the commercial electroporation system cannot
complete transfection efficiently. This success may serve as a safe and effective non-viral
gene delivery to help multiple cell sizes and types of immunotherapy work effectively.
We have also developed a new microfluidic electroporation approach with a
combination of nanosecond and millisecond pulses to enhance plasmid DNA transfection
without sacrifice on cell viability. For adherent cells (i.e., CT-26) and suspension cells
(i.e., K562), transgene expression of GFP plasmid is more than doubled at the same cell
viability levels as in standard msEP electroporation. Promotion on nuclear entry by
nanosecond pulses and the suppression of gas bubbles with the microfluidic operation is
believed to be the two major contributions by this new system on the transfection
enhancement. Having nsEP first and msEP followed immediately is found to work more
effectively than other cases with either the opposite operation order or having a long
waiting period between the two types of pulse treatments. This new microfluidic nsEP
and msEP combination treatment not only facilitates plasmid delivery and expression but
also eliminates the electrohydrolysis-induced apoptosis and low cell viability issues
commonly tied with nanosecond pulse treatments. Its success may benefit many biology
studies and clinical practice in understanding gene functions, controlling cellular signals,
screening drugs, and applying cell-based therapeutic technologies.
We did some preliminary tests on model blood cell mixture, using primary red
blood cells and T cells as well as the whole blood cells. Further studies on its
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effectiveness on the whole blood, particularly in those different primary immune cells
and red cells carry on therapeutic probes will be studied.
6.2

Future Work

In this dissertation, we have already demonstrated by several studies that coupling
nanosecond electroporation and Carbon Nanotube Micropillars Electroporation can
achieve a better electroporation efficiency than commercial electroporation device in
various cells including T cells and blood cells. Unfortunately, limited by the cells and
animal resources, we have not extensively applied this new coupling system on real
patient T cells, blood cell samples, or the animal models yet. So, in the future, we hope to
cooperate with research groups in MD Anderson and Southwestern medical centers to
apply this mRNA/DNA probes vaccine to T cells and whole blood cell samples by the
nsEP+CNTPs system. Two types of immunotherapy strategies will be evaluated with this
nsEP+CNTPs system to transfect mRNA encoding probes (e.g., Ovalbumin) to T cells
and the whole blood samples.
For direct T-cell based immunotherapy, primary T cells will be collected, purified,
and transfected with various DNA and mRNA probes. Both activated and non-activated
T cells will be transfected. Optimal pulse conditions and loading dosages of therapeutic
probes will be established, the loading efficiency of DNA and mRNA probes together
with their expression kinetics will be monitored following 3 to 7 days post-delivery. After
transfection, the treated T cells can be co-cultured with cancer cells (e.g., Melanoma) to
evaluate the functions of those treated T cells. By testing the inhibitory effect of cancer
cells and the cytokines expressed by cytotoxic T lymphocyte, we can determine if the
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primary T cells with the mRNA probes are functional after receiving nsEP+CNTPs
electroporation.
The nsEP+CNTPs system can also be used to deliver mRNA vaccines to human
whole blood samples for vaccine-type immunotherapy. In this treatment, all cells in the
blood samples will receive a quick electroporation treatment by the nsEP+CNTPs
system. Encoding cancer antigens mRNA/DNA vaccines will be delivered to different
types of blood cells, including lymphocytes, reticulocytes, and erythrocytes. The
mRNA/DNA loading level in each of these blood cell types can be measured to
determine the electroporation efficiency of the nsEP+CNTPs system. The blood cells
containing mRNA/DNA vaccines will then be co-cultured with Antigen Presenting Cells
(APCs) and then T cells. Those trained T cells will then be co-cultured with target cancer
cells like in T cell immunotherapy described early. The T Cell Receptor proteins on the T
cells’ membrane, the secretion efficiency of cytokines, and the inhibitory efficiency of
cancer cells can then be measured to test the effectiveness of the nsEP+CNTPs system in
the whole blood vaccine-based immunotherapy.
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